

1 **WO**

2  
3  
4  
5  
6 **IN THE UNITED STATES DISTRICT COURT**  
7 **FOR THE DISTRICT OF ARIZONA**  
8

9 IN RE: Bard IVC Filters Products  
10 Liability Litigation,  
11  
12

No. MDL 15-02641-PHX-DGC

**TRANSFER ORDER (FOURTH)**

13  
14 This multidistrict litigation proceeding (“MDL”) involves personal injury cases  
15 brought against Defendants C. R. Bard, Inc. and Bard Peripheral Vascular, Inc.  
16 (collectively, “Bard”). Bard manufactures and markets medical devices, including inferior  
17 vena cava (“IVC”) filters. The MDL Plaintiffs have received implants of Bard IVC filters  
18 and claim they are defective and have caused Plaintiffs to suffer serious injury or death.

19 The MDL was transferred to this Court in August 2015 when 22 cases had been  
20 filed. Doc. 1. More than 8,000 cases had been filed when the MDL closed on May 31,  
21 2019. Docs. 18079, 18128. Thousands of cases pending in the MDL have settled or are  
22 near settlement. *See* Docs. 16343, 19445, 19798, 21167, 21410. The remaining cases no  
23 longer benefit from centralized proceedings.

24 On August 20, 2019, the Court suggested the remand of 35 cases that were  
25 transferred to this MDL by the United States Judicial Panel for Multidistrict Litigation  
26 (the “Panel”), and transferred more than 500 cases that were directly filed in the MDL to  
27 appropriate districts. Doc. 19899 at 2-6, 34-59. The Court suggested the remand of another  
28 case and transferred nearly 400 cases on October 17, 2019. Doc. 20672 at 2-4, 32-48. On

1 March 4, 2020, the Court suggested the remand of 30 cases and transferred more than 1,000  
2 cases. Doc. 21462 at 2-4, 33-74 (as amended by Docs. 21463, 21472).

3 In an updated report on the settlement status of cases, the parties identify more than  
4 100 pending cases that are not likely to settle. Docs. 21552 at 2, 21552-2. These cases –  
5 which were directly filed in the MDL – will be transferred to appropriate districts pursuant  
6 to 28 U.S.C. § 1404(a). The cases to be transferred are listed on Schedule A to this order.  
7 Two other cases – *Bernadette McBride v. C. R. Bard, Inc.*, No. 2:19-cv-02819, and *Lonnie*  
8 *Easton v. C. R. Bard, Inc.*, No. 2:19-cv-04274 – will be unconsolidated from the MDL,  
9 will remain in the District of Arizona, and will be assigned to the undersigned judge. *See*  
10 Doc. 21552-2 at 1, 3.

11 To assist the transferee courts, this order will describe events that have taken place  
12 in the MDL. A copy of this order, along with the case files and materials, will be available  
13 to courts after transfer.

14 **I. Transfer Under 28 U.S.C. § 1404(a).**

15 Pursuant to Case Management Order No. 4 (“CMO 4”), cases were filed directly in  
16 the MDL through use of a short form complaint. Doc. 363 at 3 (as amended by Docs. 1108,  
17 1485). Plaintiffs were required to identify in the short form complaint the district where  
18 venue would be proper absent direct filing in the MDL. *See id.* at 7. CMO 4 provides that,  
19 upon the MDL’s closure, each pending direct-filed case shall be transferred to the district  
20 identified in the short form complaint. *Id.* at 3.

21 Section 1404(a) provides that “[f]or the convenience of parties and witnesses, in the  
22 interest of justice, a district court may transfer any civil action to any other district or  
23 division where it might have been brought or to any district or division to which all parties  
24 have consented.” Pursuant to § 1404(a), the Court will transfer the cases listed on Schedule  
25 A to the districts identified in the short form complaints. *See In re Biomet M2a Magnum*  
26 *Hip Implant Prods. Liab. Litig.*, No. 3:12-MD-2391, 2018 WL 7683307, at \*1 (N.D. Ind.  
27 Sept. 6, 2018) (transferring cases under § 1404(a) where they would “no longer benefit  
28 from centralized proceedings[] and the remaining case-specific issues are best left to

1 decision by the courts that will try the cases”). Defendants’ right to challenge venue and  
2 personal jurisdiction upon transfer is preserved. *See* Docs. 19899 at 4-6, 20672 at 4, 21426  
3 at 4.

## 4 **II. The MDL Proceedings.**

5 A summary of the MDL proceedings is provided below to assist courts receiving  
6 transfers under § 1404(a). CMOs, discovery orders, and other significant rulings are listed  
7 in Exhibit 1. The status of the remaining case-specific discovery and other pretrial issues  
8 in individual cases should be addressed by the transferee courts.

### 9 **A. Plaintiffs’ Claims and the Pleadings.**

10 The IVC is a large vein that returns blood to the heart from the lower body. An IVC  
11 filter is a small device implanted in the IVC to catch blood clots before they reach the heart  
12 and lungs. This MDL involves multiple versions of Bard’s retrievable IVC filters – the  
13 Recovery, G2, G2X, Eclipse, Meridian, and Denali. These filters are umbrella-shaped  
14 devices that have multiple limbs fanning out from a cone-shaped head. The limbs consist  
15 of legs with hooks that attach to the IVC wall and curved arms to catch or break up blood  
16 clots. Each of these filters is a variation of its predecessor.<sup>1</sup>

17 The MDL Plaintiffs allege that Bard filters are more dangerous than other IVC  
18 filters because they have higher risks of tilting, perforating the IVC, or fracturing and  
19 migrating to vital organs. Plaintiffs further allege that Bard failed to warn patients and  
20 physicians about these higher risks. Defendants dispute these allegations, contending that  
21 Bard filters are safe and effective, that their complication rates are low and comparable to  
22 those of other IVC filters, and that the medical community is aware of the risks associated  
23 with IVC filters.

24 CMO 2, entered October 30, 2015, required the creation of a master complaint, a  
25 master answer, and templates of short-form complaints and answers. Doc. 249 at 6. The

---

26  
27 <sup>1</sup> In early 2019, Defendants moved to expand the scope of the MDL to include cases  
28 concerning Bard’s Simon Nitinol Filter (“SNF”), a permanent device that predated the  
other filters in this litigation. The Panel denied the motion as moot because more than 80  
SNF cases already had been filed in the MDL. None of the SNF cases are subject to this  
order.

1 master complaint and answer were filed December 12, 2015. Docs. 364, 366. They are  
2 the operative pleadings for most of the cases in this MDL.

3 The master complaint gives notice, pursuant to Rule 8, of the allegations that  
4 Plaintiffs assert generally. The master complaint contains seventeen state law claims:  
5 manufacturing defect (Counts I and V); failure to warn (Counts II and VII); design defect  
6 (Counts III and IV); failure to recall (Count VI); misrepresentation (Counts VIII and XII);  
7 negligence per se (Count IX); breach of warranty (Counts X and XI); concealment (Count  
8 XIII); consumer fraud and deceptive trade practices (Count XIV); loss of consortium  
9 (Count XV); and wrongful death and survival (Counts XVI and XVII). Doc. 364 at 34-63.  
10 Plaintiffs seek both compensatory and punitive damages. *Id.* at 63.

11 Plaintiff-specific allegations are contained in individual short-form complaints or  
12 certain complaints served on Defendants before the filing of the master complaint. *See*  
13 Docs. 249, 363, 365. Plaintiffs also provided Defendants with profile forms and fact sheets  
14 that describe their individual claims and conditions. *See* Doc. 365.

#### 15 **B. Case Management Orders.**

16 The primary orders governing pretrial management of this MDL are a series  
17 of CMOs, along with certain amendments. To date, the Court has issued 47 CMOs. These  
18 orders are discussed below and can be found on this District's website at  
19 <http://www.azd.uscourts.gov/case-info/bard>.

#### 20 **C. Lead Counsel.**

21 CMO 1, entered October 30, 2015, appointed Co-Lead/Liaison Counsel for  
22 Plaintiffs ("Lead Counsel") to manage the litigation on behalf of Plaintiffs, and set out the  
23 responsibilities of Lead Counsel. Doc. 248. Plaintiffs' Lead Counsel has changed since  
24 the inception of the MDL. Mr. Ramon Lopez, of Lopez McHugh, LLP, in Newport Beach,  
25 California, and Mr. Mark O'Connor, of Beus Gilbert McGroder PLLC, in Phoenix,  
26 Arizona, are now Lead Counsel for Plaintiffs. Doc. 5285. Mr. Richard North of Nelson  
27 Mullins Riley & Scarborough, LLP, in Atlanta, Georgia, is Defendants' Lead Counsel.

#### 28 **D. Plaintiffs' Steering Committee and Common Benefits Fund.**

1 CMO 1 directed the selection and appointment of a Plaintiffs' Steering Committee  
2 ("PSC") to assist in the coordination of pretrial activities and trial planning. Plaintiffs'  
3 Lead Counsel and the PSC together form the Plaintiffs' Leadership Counsel ("PLC"). The  
4 PLC assists all Plaintiffs in the MDL by overseeing discovery, appearing in court, attending  
5 status conferences, and preparing motions and responses regarding case-wide discovery  
6 matters. CMO 1 has been amended to select and appoint a Plaintiffs' Executive Committee  
7 ("PEC") to assist Lead Counsel in the administration, organization, and strategic decisions  
8 of the PLC. Doc. 4016. The configuration of the PSC has changed during the course of  
9 the litigation. *See* Docs. 248, 4016, 5285.

10 CMO 6, entered December 18, 2015, set forth rules, policies, procedures, and  
11 guidelines for fees and expenses incurred by attorneys acting for the common benefit of all  
12 MDL Plaintiffs. Doc. 372. In May 2019, the Court increased the common benefit  
13 attorneys' fees assessment from 6% to 8%, but declined to increase the 3% assessment for  
14 costs. Doc. 18038.

15 Upon transfer, individual Plaintiffs likely will be represented by their own counsel  
16 – the attorney or attorneys who filed their original complaint. Plaintiffs' Lead Counsel, the  
17 PSC, the PLC, and the PEC were tasked with managing the MDL for Plaintiffs, not the  
18 individual cases upon transfer.

#### 19 **E. Status Conferences.**

20 Since the inception of the MDL, the Court has held regular status conferences with  
21 Lead Counsel for the parties to discuss issues related to the litigation. The initial case  
22 management conference was held in October 2015. Doc. 246. Deadlines were set for,  
23 among other things, the filing of master and short-form pleadings, profile forms, a proposed  
24 protective order (including Rule 502 provisions), a proposed protocol governing the  
25 production of electronically stored information ("ESI"), as well as deadlines to complete  
26 first-phase MDL discovery and address privilege log issues. Doc. 249. Thereafter, the  
27 Court held periodic status conferences to ensure that the parties were on task and to address  
28 routine discovery issues and disputes. In addition to the status conferences, the Court

1 conducted telephone hearings to address time-sensitive issues, as well as numerous  
2 additional conferences to consider various matters such as dispositive motions and general  
3 case management issues.

4 **F. Discovery.**

5 **1. General Fact Discovery.**

6 Prior to the establishment of this MDL, Plaintiffs' counsel had conducted substantial  
7 discovery against Bard concerning all aspects of Bard IVC filters, including the design,  
8 testing, manufacturing, marketing, labeling, and post-market surveillance of the devices.  
9 Bard produced numerous documents and ESI and responded to thousands of written  
10 discovery requests, and more than 80 corporate witness depositions were taken. The  
11 pre-MDL fact discovery was made available by Bard to all Plaintiffs in the MDL.

12 CMO 8 established a procedure concerning re-deposing witnesses in the MDL.  
13 Doc. 519. CMO 14 established deposition protocols generally. Doc. 2239. The Court  
14 allowed additional depositions of a handful of corporate witnesses that had been previously  
15 deposed, as well as numerous depositions of other Bard corporate witnesses, including  
16 several Rule 30(b)(6) depositions. Docs. 3685, 4311. CMO 9 governed the production of  
17 ESI and hard-copy documents. Doc. 1259.

18 Discovery in the MDL was separated into phases. The parties completed the first  
19 phase of MDL discovery in early 2016. Doc. 519. The first phase included production of  
20 documents related to an FDA inspection and warning letter to Bard, an updated production  
21 of complaint and adverse event files, and an updated version of Bard's complaint database  
22 relating to IVC filters. Doc. 249. Plaintiffs also conducted a Rule 30(b)(6) deposition  
23 concerning the FDA inspection and warning letter, and a deposition of corporate witness  
24 Kay Fuller.

25 The parties completed the second phase of fact discovery in February 2017. CMO 8  
26 set deadlines for the second phase, which included all common fact and expert issues in  
27 the MDL, but not case-specific issues to be resolved after remand or transfer. Docs. 249,  
28 519. Second-phase discovery included extensive additional discovery related to Bard's

1 system architecture for ESI, Bard's ESI collection efforts, ESI relating to Bard's IVC  
2 filters, and Bard's national and regional sales and marketing practices. Plaintiffs also  
3 deposed two corporate witnesses in connection with Kay Fuller's allegations that a  
4 submission to the FDA regarding the Recovery filter did not bear her original signature.  
5 Doc. 1319 (CMO 10). Plaintiffs deposed additional corporate witnesses concerning the  
6 FDA inspections and warning letter. *Id.*

7 Bard also produced discovery regarding the sales and marketing materials related to  
8 the SNF, documents comparing filter performance and failure rates to the SNF, and internal  
9 and regulatory communications relating to the SNF. Docs. 1319, 10489. The Court denied  
10 Plaintiffs' request to obtain ESI discovery from Bard's overseas operations. Doc. 3398.  
11 The Court also denied Defendants' request to discover communications between Plaintiffs'  
12 counsel and NBC news related to stories about the products at issue in this litigation, and  
13 third-party financing that may be in place with respect to MDL Plaintiffs. Docs. 3313,  
14 3314. Plaintiffs were required to produce communications between Plaintiffs and the FDA  
15 related to the FDA warning letter, but the Court denied Defendants' request to depose  
16 Plaintiffs' counsel regarding these communications. Docs. 3312, 4339. Defendants also  
17 produced punitive damages discovery, and Plaintiffs conducted a Rule 30(b)(6) deposition  
18 related to Bard's net worth.

19 All common fact discovery has now been completed, including preservation  
20 depositions for certain witnesses who will not be traveling to testify live at the trials of  
21 transferred cases. *See* Docs. 16343, 19959, 21063. Thus, courts receiving these cases need  
22 not be concerned with facilitating general fact discovery on remand or transfer.

## 23 **2. Case-Specific Discovery.**

24 CMO 5 governed initial case-specific discovery and required the parties to exchange  
25 abbreviated profile forms. Doc. 365 (as amended by Doc. 927). Plaintiffs were required  
26 to provide Defendants with a Plaintiff profile form ("PPF") that described individual  
27 conditions and claims. *Id.* at 5-9. Upon receipt of a substantially complete PPF,  
28 Defendants were required to provide the individual Plaintiff with a Defendants' profile

1 form (“DPF”) that disclosed information and documents concerning Defendants’ contacts  
2 and relationship with Plaintiff’s physicians, tracking and reporting of Plaintiff’s claims,  
3 and certain manufacturing related information for Plaintiff’s filter. *Id.* at 12-14. Completed  
4 profile forms were considered interrogatory answers under Rule 33 or responses to requests  
5 for production under Rule 34, and were governed by the standards applicable to written  
6 discovery under Rules 26 through 37. *Id.* at 2-3. CMO 5 also set deadlines and procedures  
7 for resolving any purported deficiencies with the parties’ profile forms, and for dismissal  
8 of cases that did not provide substantially completed profile forms. *Id.* at 2.<sup>2</sup>

9 Further discovery was conducted in a group of 48 cases (“Group 1”) selected for  
10 consideration in the bellwether trial process from the pool of cases filed and properly  
11 served on Defendants in the MDL as of April 1, 2016 (“Initial Plaintiff Pool”). Docs. 1662,  
12 3214, 4311 (CMOs 11, 15, 19). Plaintiffs in Group 1 were required to provide Defendants  
13 with a Plaintiff fact sheet (“PFS”) that described their individual conditions and claims in  
14 greater detail, and provided detailed disclosures concerning their individual background,  
15 medical history, insurance, fact witnesses, prior claims, and relevant documents and  
16 records authorizations. Docs. 1153-1, 1662 at 3.

17 Upon receipt of a PFS, Defendants were required to provide the individual Plaintiff  
18 with a Defendants fact sheet (“DFS”) that disclosed in greater detail information  
19 concerning Defendants’ contacts and relationship with Plaintiff, Plaintiff’s physicians, or  
20 anyone on behalf of Plaintiff, Defendants’ tracking and reporting of Plaintiff’s claims, sales  
21 and marketing information for the implanting facility, manufacturing information for  
22 Plaintiff’s filter, and other relevant documents. Docs. 1153-2, 1662 at 3. Completed fact  
23 sheets were considered interrogatory answers under Rule 33 or responses to requests for  
24 production under Rule 34, and were governed by the standards applicable to written  
25 discovery under Rules 26 through 37. Doc. 1662 at 3. CMO 11 set deadlines and  
26 procedures for resolving any purported deficiencies with the parties’ fact sheets. *Id.* at 2,

---

27  
28 <sup>2</sup> The Court has dismissed certain cases where Plaintiffs failed to provide complete  
PPFs. *See* Docs. 19874, 20667, 21579.



1 4-5. CMO 12 governed records discovery for Group 1. Doc. 1663. The parties agreed to  
2 use The Marker Group to collect medical, insurance, Medicare, Medicaid, prescription,  
3 Social Security, workers' compensation, and employment records for individual plaintiffs  
4 from third-parties designated as custodians for such records in the PFS. *Id.* at 1.

5 From Group 1, twelve cases were selected for further consideration as bellwether  
6 cases ("Discovery Group 1"). Docs. 1662, 3685, 4311 (CMOs 11, 18, 19). CMO 20 set  
7 deadlines for preliminary case-specific discovery in that group. Doc. 4335. Pursuant to  
8 the protocols set in CMOs 14 and 21, the parties were permitted to depose each Plaintiff,  
9 his or her spouse or a significant family member, the implanting physician, an additional  
10 treating physician, and either a Bard sales representative or supervisor. Docs. 2239, 4866  
11 at 1-2. From Discovery Group 1, six Plaintiffs were selected for potential bellwether trials  
12 and further case-specific discovery ("Bellwether Group 1"). Docs. 1662, 3685, 4311,  
13 5770, 11659 (CMOs 11, 18, 19, 23, and 34).

14 Except for the 48 cases in Group 1, the parties did not conduct case-specific fact  
15 discovery for the cases listed on Schedule A during the MDL proceedings, other than  
16 exchanging abbreviated profile forms. The Court concluded that any additional case-  
17 specific discovery in these cases should await their transfer. Thus, courts receiving these  
18 cases should set a schedule for the completion of case-specific discovery.

### 19 **3. Expert Discovery.**

20 CMO 8 governed expert disclosures and discovery. Doc. 519. The parties  
21 designated general experts in all MDL cases and case-specific experts in individual  
22 bellwether cases. General expert discovery closed July 14, 2017. Doc. 3685 (CMO 18).  
23 The parties did not conduct case-specific expert discovery for the cases listed on Schedule  
24 A during the MDL proceedings. The Court concluded that case-specific expert discovery  
25 in these cases should await their transfer. Thus, courts receiving these cases should set a  
26 schedule for the completion of case-specific expert discovery.

27 ///

28 ///

#### 4. Privileged Materials.

CMO 2 required Defendants to produce privilege logs in compliance with the Federal Rules of Civil Procedure. Doc. 249. The parties were then required to engage in an informal privilege log meet and confer process to resolve any privilege disputes. Defendants produced several privilege logs identifying documents withheld pursuant to the attorney-client privilege, the work-product doctrine, and other privileges. The parties regularly met and conferred regarding the privilege logs and engaged in negotiations regarding certain entries identified by Plaintiffs. As part of that meet and confer process, Defendants provided Plaintiffs with a small number of these identified items for inspection and, in some cases, withdrew certain claims of attorney-client privilege and produced the previously withheld items.

CMO 3 governed the non-waiver of any privilege or work-product protection in this MDL, pursuant to Federal Rule of Evidence 502(d), by Defendants' disclosure or production of documents on its privilege logs as part of the meet and confer process. Doc. 314.

In late 2015, Plaintiffs challenged a substantial number of documents on Defendants' privilege log. The parties engaged in an extensive meet and confer process, and Defendants produced certain documents pursuant to the Rule 502(d) order. *See id.* Plaintiffs moved to compel production of 133 disputed documents. The Court granted the motion in part. Doc. 2813. The parties identified several categories of disputed documents and provided sample documents for in camera review. The Court denied Plaintiffs' motion with respect to seven of eight categories of documents and found only one of the sample documents in one of the categories to contain unprivileged portions that should be produced. The Court found all other documents protected by the attorney-client privilege or work product doctrine. The Court directed the parties to use this ruling as a guide to resolve remaining privilege disputes.

Since this ruling, there have been no further challenges to Defendants' privilege logs. Defendants continued to provide updated privilege logs throughout the discovery

1 process, and the parties met and conferred to resolve privilege disputes. Privilege issues  
2 should not be a concern for courts that receive these cases.

### 3 **5. Protective Order and Confidentiality.**

4 A stipulated protective order governing the designation, handling, use, and  
5 disclosure of confidential discovery materials was entered in November 2015. Doc. 269.  
6 CMO 7, entered January 5, 2016, governed redactions of material from additional adverse  
7 event reports, complaint files, and related documents in accordance with the Health  
8 Insurance Portability Act of 1996 (“HIPAA”) and under 21 C.F.R. § 20.63(f). Doc. 401.

9 In September 2016, to expedite production of ESI, the parties agreed to a primarily  
10 “no-eyes-on” document production as to relevancy while still performing a privilege  
11 review for this expedited ESI document production. CMO 17 (Doc. 3372) modified the  
12 protections and requirements in the stipulated protective order (Doc. 269) and CMO 7  
13 (Doc. 401) for ESI produced pursuant to this process. CMO 17 was amended in November  
14 2016. Doc. 4015.

15 Defendants filed a motion to seal certain trial exhibits at the conclusion of the first  
16 bellwether trial. Doc. 11010. The Court denied this motion and Defendants’ subsequent  
17 motion for reconsideration. Docs. 11642, 11766, 12069. Defendants also filed a motion  
18 to enforce the protective order for the second and third bellwether trials collectively. Doc.  
19 13126. This motion was denied. Doc. 14446. A list of exhibits admitted at the bellwether  
20 trials (excluding case-specific medical records) and documents deemed no longer subject  
21 to the protective order are attached as Exhibit 2.

### 22 **G. Bellwether Cases and Trials.**

23 Six Plaintiffs were selected for potential bellwether trials. Docs. 5770, 11659  
24 (CMOs 23, 34). The Court held three bellwether trials: *Booker*, No. 2:16-cv-00474, *Jones*,  
25 No. 2:16-cv-00782, and *Hyde*, No. 2:16-cv-00893. The Court granted summary judgment  
26 in one of the bellwether cases, *Kruse*, No. 2:15-cv-01634, and removed another from the  
27 bellwether trial schedule at the request of Plaintiffs, *Mulkey*, No. 2:16-cv-00853. Docs.  
28 12202, 13329. The final bellwether case, *Tinlin*, No. 2:16-cv-00263, settled shortly before

1 trial in May 2019. The Court determined that further bellwether trials were not necessary.  
2 Docs. 12853, 13329 (CMOs 38, 40).

3 **1. Booker, No. 2:16-cv-00474.**

4 The first bellwether trial concerned Plaintiff Sherr-Una Booker and involved a Bard  
5 G2 filter. The filter had tilted, migrated, and fractured. Plaintiff required open heart  
6 surgery to remove the fractured limbs and repair heart damage caused by a percutaneous  
7 removal attempt. Plaintiff withdrew her breach of warranty claims before Defendants  
8 moved for summary judgment. The Court granted Defendants' motion for summary  
9 judgment on the claims for manufacturing defects, failure to recall, misrepresentation,  
10 negligence per se, and breach of warranty. Docs. 8873, 8874. The remaining claims for  
11 failure to warn, design defect, and punitive damages were tried to a jury over a three-week  
12 period in March 2018.

13 The jury found for Plaintiff Booker on her negligent failure-to-warn claim, and in  
14 favor of Defendants on the design defect and strict liability failure-to-warn claims.  
15 Doc. 10595. The jury returned a verdict of \$2 million in compensatory damages (of which  
16 \$1.6 million was attributed to Defendants after apportionment of fault) and \$2 million in  
17 punitive damages. *Id.*; Doc. 10596. The Court denied Defendants' motions for judgment  
18 as a matter of law and a new-trial. Docs. 10879, 11598.

19 Defendants appealed, arguing that the Court erred by denying summary judgment  
20 on their preemption defense, that a failure-to-warn claim was unavailable, and that the  
21 award of punitive damages was not supported by the evidence. *See* Docs. 11934, 11953.  
22 The Ninth Circuit affirmed. *See In re Bard IVC Filters Prods. Liab. Litig.*, No. 18-16349  
23 (Doc. 77), 2020 WL 4692349 (9th Cir. Aug. 13, 2020). Defendants' petition for panel  
24 rehearing and rehearing en banc is pending. *See* No. 18-16349, Doc. 78.<sup>3</sup>

25 ///

26 ///

27 \_\_\_\_\_

28 <sup>3</sup> Plaintiff filed and later dismissed with prejudice a cross-appeal. Docs. 12070, 17916.

1                   **2.     *Jones, No. 2:16-cv-00782.***

2           The second bellwether trial concerned Plaintiff Doris Jones and involved a Bard  
3 Eclipse filter. Plaintiffs withdrew the manufacturing defect, failure to recall, and breach of  
4 warranty claims. The Court granted summary judgment on the misrepresentation,  
5 negligence per se, and unfair trade practices claims. Doc. 10404. The remaining claims  
6 for failure to warn, design defect, and punitive damages were tried to a jury over a  
7 three-week period in May 2018. The jury returned a defense verdict. Doc. 11350. Plaintiff  
8 filed a motion to contact the jurors, which was denied. Docs. 11663, 12068.

9           Plaintiff appealed the Court's rulings excluding cephalad migration death evidence.  
10 Docs. 12057, 12071. The Ninth Circuit affirmed those rulings. *See In re Bard IVC Filters*  
11 *Prods. Liab. Litig.*, No. 18-16461 (Doc. 51), 2020 WL 4719266, at \*1 (9th Cir. Aug. 13,  
12 2020). Plaintiff's petition for rehearing en banc is pending. *See* No. 18-16461, Doc. 53.

13                   **3.     *Kruse, No. 2:15-cv-01634.***

14           Plaintiff Carol Kruse's case was set for trial in September 2018. The Court granted  
15 Defendants' summary judgment motion on statute of limitations grounds. Doc. 12202.

16                   **4.     *Hyde, No. 2:16-cv-00893.***

17           The third bellwether trial concerned Plaintiff Lisa Hyde and involved either a Bard  
18 G2X or Eclipse filter (the exact model was in dispute). Ms. Hyde's case was moved to the  
19 September 2018 bellwether slot in lieu of Ms. Kruse's case. Doc. 11867. Plaintiffs  
20 withdrew their claims for manufacturing defect and breach of express warranty. The Court  
21 granted summary judgment on the claims for breach of implied warranty, failure to warn,  
22 failure to recall, misrepresentation, concealment, and fraud. Doc. 12007. The Court also  
23 entered judgment in favor of Defendants on the negligence per se claim after concluding  
24 that it was impliedly preempted under 21 U.S.C. § 337(a). Doc. 12589. The remaining  
25 claims for design defect, loss of consortium, and punitive damages were tried to a jury over  
26 three weeks in September 2018. After the close of Plaintiffs' evidence, the Court granted  
27 in part Defendants' motion for judgment as a matter of law with respect to future damages  
28 for any cardiac arrhythmia Ms. Hyde may experience, but denied the motion as to the

1 remaining claims. Doc. 12805. The jury returned a defense verdict. Doc. 12891. Plaintiff  
2 has appealed. Docs. 13465, 13480.

3 **5. *Mulkey*, No. 2:16-cv-00853.**

4 Plaintiff Debra Mulkey's case involved an Eclipse filter and was set for trial in  
5 February 2019. Before trial, Plaintiffs asked the Court to remove the Mulkey case from  
6 the bellwether trial schedule because it was similar to the Jones and Hyde cases and would  
7 not provide meaningful information to the parties. Doc. 12990. The Court granted the  
8 motion. Doc. 13329.

9 **6. *Tinlin*, No. 2:16-cv-00263.**

10 The final bellwether trial concerned Plaintiff Debra Tinlin and involved a Bard  
11 Recovery filter. Plaintiffs withdrew their claims for manufacturing defect, failure to recall,  
12 negligence per se, and breach of warranty. The Court granted summary judgment on the  
13 misrepresentation and deceptive trade practices claims. Doc. 17008. The remaining claims  
14 for failure to warn, design defect, concealment, loss of consortium, and punitive damages  
15 were scheduled for trial in May 2019, but the case settled.

16 **H. Key Legal and Evidentiary Rulings.**

17 The Court has made many rulings in this MDL that could affect the remanded and  
18 transferred cases. The Court provides the following summary of key legal and evidentiary  
19 rulings to assist the courts that receive these cases.

20 **1. Medical Monitoring Class Action Ruling.**

21 In May 2016, Plaintiffs' counsel filed a medical monitoring class action that was  
22 consolidated with the MDL. *See Barraza v. C. R. Bard, Inc.*, No. 2:16-cv-01374 (D. Ariz.  
23 May 5, 2015). The *Barraza* Plaintiffs moved for class certification for medical monitoring  
24 relief on behalf of themselves and classes of individuals who have been implanted with a  
25 Bard IVC filter, have not had that filter removed, and have not filed a claim or lawsuit for  
26 personal injury related to the filter. *Id.*, Doc. 54. The Court declined to certify the class.  
27 *Id.*, Doc. 95.

1       The class certification motion recognized that only 16 states permit claims for  
2 medical monitoring. The Court concluded that the classes could not be certified under Rule  
3 23(b)(3) because individual issues would predominate. *Id.* at 20-21. The Court further  
4 concluded that the class could not be certified under Rule 23(b)(2) because the medical  
5 monitoring relief primarily constituted monetary rather than injunctive relief, and the class  
6 claims were not sufficiently cohesive to permit binding class-wide relief. *Id.* at 21-32.  
7 Finally, the Court concluded that typicality under Rule 23(a)(3) had not been established.  
8 *Id.* at 32-34. The *Barazza* Plaintiffs dismissed their claims without prejudice. Docs. 106,  
9 107. No appeal has been filed.

## 10                   **2.       Federal Preemption Ruling.**

11       Defendants moved for summary judgment on the grounds that Plaintiffs' state law  
12 claims are expressly preempted by the Medical Device Amendments of 1976 ("MDA"),  
13 21 U.S.C. § 360 et seq., and impliedly preempted by the MDA under the Supreme Court's  
14 conflict preemption principles. Doc. 5396. The Court denied the motion. Doc. 8872.

15       The MDA curtails state regulation of medical devices through a provision that  
16 preempts state requirements that differ from or add to federal requirements. 21 U.S.C.  
17 § 360k. The Bard IVC filters at issue in this litigation were cleared for market by the FDA  
18 through section "510k" review, which focuses primarily on equivalence rather than safety  
19 and effectiveness. *See* § 360c(f)(1)(A).

20       The Supreme Court in *Medtronic, Inc. v. Lohr*, 518 U.S. 470 (1996), held that  
21 § 360k does not preempt state law claims directed at medical devices cleared through  
22 the 510(k) process because substantial equivalence review places no federal requirements  
23 on a device. *Id.* at 492-94. *Lohr* also noted that the "510(k) process is focused on  
24 *equivalence*, not safety." *Id.* at 493 (emphasis in original). Although the Safe Medical  
25 Devices Act of 1990 ("SMDA"), Pub. L. 101-629, injected safety and effectiveness  
26 considerations into 510(k) review, it did so only comparatively. The Court found that *Lohr*  
27 remains good law and that clearance of a product under 510(k) generally does not preempt  
28 state common law claims. Doc. 8872 at 12-14.

1           The Court further found that Defendants failed to show that the 510(k) reviews for  
2 Bard IVC filters imposed device-specific requirements as needed for preemption under  
3 § 360k. *Id.* at 14-20. Even if device-specific federal requirements could be ascertained,  
4 Defendants made no showing that any particular state law claim is expressly preempted by  
5 federal requirements. *Id.* at 21-22.

6           The Court concluded that Plaintiffs' state law claims are not impliedly preempted  
7 because Defendants failed to show that it is impossible to do under federal law what the  
8 state laws require. *Id.* at 22-24.

9           Defendants pursued their preemption arguments in the Booker appeal. *See Docs.*  
10 11934, 11953. As noted, the Ninth Circuit affirmed the Court's preemption ruling. *See In*  
11 *re Bard IVC Filters Prods. Liab. Litig.*, No. 18-16349, 2020 WL 4692349, at \*1-6 (9th Cir.  
12 Aug. 13, 2020).

### 13                           **3.     The Lehmann Report Privilege and Work Product Rulings.**

14           The Court granted Defendants' motion for a protective order to prevent Plaintiffs  
15 from using a December 15, 2004 report of Dr. John Lehmann. Doc. 699. Dr. Lehmann  
16 provided various consulting services to Bard at different times. Following Bard's receipt  
17 of potential product liability claims involving the Recovery filter, Bard's legal department  
18 retained Dr. Lehmann in November 2004 to provide an assessment of the risks associated  
19 with the Recovery filter and the extent of Bard's legal exposure. Dr. Lehmann prepared a  
20 written report of his findings at the request of the legal department and in anticipation of  
21 litigation. The Court found the report to be protected from disclosure by the work product  
22 doctrine. *Id.* at 4-12. The Court further found that Plaintiffs had not shown a substantial  
23 need for the report or undue hardship if the report was not disclosed. *Id.* at 13-15. The  
24 Court agreed with the parties that this ruling does not alter any prior rulings by transferor  
25 judges in specific cases. *Id.* at 22.

### 26                           **4.     Daubert Rulings.**

27           The Court has ruled on *Daubert* motions directed at general experts, and refers the  
28 remand and transfer courts to the following orders:



<b><i>Daubert Order</i></b>	<b>Doc. Nos.</b>
Plaintiffs' Expert Dr. Thomas Kinney	9428, 10323
Plaintiffs' Experts Drs. Scott Resnick, Robert Vogelzang, Kush Desai, and Robert Lewandowski	9432
Plaintiffs' Experts Drs. David Kessler and Suzanne Parisian	9433
Plaintiffs' Experts Drs. Thomas Kinney, Anne Christine Roberts, and Sanjeeva Kalva	9434
Plaintiffs' Expert Dr. Mark Eisenberg	9770
Plaintiffs' Expert Dr. Derek Muehrcke	9771
Plaintiffs' Expert Dr. Darren Hurst	9772
Plaintiffs' Expert Dr. Rebecca Betensky	9773
Defendants' Expert Dr. Clement Grassi	9991, 10230
Plaintiffs' Expert Dr. Robert McMeeking	10051, 16992
Plaintiffs' Expert Dr. Robert Ritchie	10052
Plaintiffs' Experts Drs. David Garcia and Michael Streiff	10072
Defendants' Expert Dr. Christopher Morris	10230, 10231, 17285

1                   **5. Motion in Limine Rulings.**

2                   **a. FDA Evidence (*Cisson* Motion).**

3           In the Booker bellwether trial, Plaintiffs sought to exclude, under Federal Rules of  
4 Evidence 402 and 403, evidence of the FDA's 510(k) clearance of Bard IVC filters and the  
5 lack of FDA enforcement action against Bard. Doc. 9529. The Court denied the motion.  
6 Docs. 9881, 10323.

7           The Court found that under Georgia law, which applied in both the Booker and  
8 Jones bellwether cases, compliance with federal regulations may not render a  
9 manufacturer's design choice immune from liability, but evidence of Bard's compliance  
10 with the 510(k) process was nonetheless relevant to the design defect and punitive damages  
11 claims. Doc. 9881 at 3-4. The Court acknowledged concerns that FDA evidence might  
12 mislead the jury or result in a mini-trial. *Id.* at 5-6 (citing *In re C.R. Bard, Inc., Pelvic*  
13 *Repair Sys. Prods. Liab. Litig. (Cisson)*, No. 2:10-CV-01224, 2013 WL 3282926, at \*2  
14 (S.D.W. Va. June 27, 2013)). But the Court concluded that such concerns could adequately  
15 be addressed by efficient management of the evidence and adherence to the Court's time  
16 limits for trial, and, if necessary, by a limiting instruction regarding the nature of the 510(k)  
17 process. *Id.* at 6-7.<sup>4</sup>

18           The Court noted that the absence of any evidence regarding the 510(k) process  
19 would run the risk of confusing the jury, as many of the relevant events in this litigation  
20 occurred in the context of the FDA's 510(k) review of the Bard filters and are best  
21 understood in that context. Doc. 9881 at 7. Nor was the Court convinced that all FDA  
22 references could adequately be removed from the evidence. *Id.*

23           The Court further concluded that it would not exclude evidence and arguments by  
24 Defendants that the FDA took no enforcement action against Bard with respect to the G2  
25 or Eclipse filters, or evidence regarding information Bard provided to the FDA in  
26 connection with the 510(k) process. Docs. 10323 at 2-3 (Booker), 11011 at 4-5 (Jones).

---

27  
28           <sup>4</sup> The Court did not find a limiting instruction necessary at the close of either the  
Booker or Jones trials. *See* Doc. 10694 at 9.

1 The Court found that the evidence was relevant to the negligent design and punitive  
2 damages claims under Georgia law. *Id.* The Court determined at trial that it had no basis  
3 to conclude that the FDA's lack of enforcement was intended by the FDA as an assertion,  
4 and therefore declined to exclude the evidence as hearsay. Doc. 10568 at 87.

5 **b. FDA Warning Letter.**

6 Defendants moved to exclude evidence of the July 13, 2015 FDA warning letter  
7 issued to Bard. Doc. 9864 at 2-3. The Court granted the motion in part, excluding as  
8 irrelevant topics 1, 2, 4(a), 4(b), 5, 6, 7, and 8 of the warning letter. Docs. 10258 at 6-8  
9 (Booker), 10805 at 1 (Jones), 12736 (Hyde), 17401 at 10 (Tinlin). Topics 1 and 2 concern  
10 the Recovery Cone retrieval system; Topic 4(a) concerns the filter cleaning process; and  
11 Topics 4(b), 5, 6, 7, and 8 concern the Denali Filter. The Court concluded that none of  
12 these topics was relevant to the issues in the bellwether cases involving a G2 filter  
13 (Booker), an Eclipse filter (Jones), either a G2X or Eclipse filter (Hyde), and a Recovery  
14 filter (Tinlin). *Id.*

15 The Court deferred ruling on the relevance of topic 3 until trial in all bellwether  
16 cases. The Court found that topic 3, concerning Bard's complaint handling and reporting  
17 of adverse events with respect to the G2 and Eclipse filters, as well as the adequacy of  
18 Bard's evaluation of the root cause of the violations, was relevant to rebut the implication  
19 at trial that the FDA took no action with respect to Bard IVC filters. *See* Doc. 10693 at 13-  
20 15; Doc. 11256. The Court concluded that the warning letter was admissible under Federal  
21 Rule of Evidence 803(8), and was not barred as hearsay. Doc. 10258 at 7. The Court  
22 further concluded that the probative value of topic 3 was not substantially outweighed by  
23 the danger of unfair prejudice to Bard under Rule 403. *Id.* The Court admitted the warning  
24 letter in redacted form during the three bellwether trials. *See* Docs. 10565, 11256, 12736.  
25 The Court noted that topic 3 included reference to the G2, the filter at issue in Booker, and  
26 reached similar conclusions in Jones and Hyde. Doc. 17401 at 11. The parties disputed  
27 the relevance of topic 3 in Tinlin because it did not include reference to the Recovery, the  
28

1 filter at issue in Tinlin. *Id.* The Court did not decide this issue because the Tinlin case  
2 settled.

3 **c. Recovery Cephalad Migration Death Evidence.**

4 Defendants moved to exclude evidence of cephalad migration (i.e., migration of the  
5 filter toward the patient's heart) by a Recovery filter resulting in patient death. The Court  
6 denied the motion for the Booker bellwether trial, which involved a G2 filter. Docs. 10258  
7 at 4-5, 10323 at 4.

8 The Court granted the motion for the Jones bellwether trial, which involved an  
9 Eclipse filter, and denied Plaintiff's requests for reconsideration of the ruling before and  
10 during the trial. *See* Docs. 10819, 10920, 11041, 11113, 11256, 11302; *see also*  
11 Doc. 11409 at 94-96. As noted, the Ninth Circuit affirmed the Court's rulings. *See In re*  
12 *Bard IVC Filters Prods. Liab. Litig.*, No. 18-16461, 2020 WL 4719266, at \*1 (9th Cir.  
13 Aug. 13, 2020). Plaintiff's petition for rehearing en banc is pending. *See* No. 18-16461,  
14 Doc. 53.

15 The Court granted the motion for the Hyde bellwether trial, which involved either a  
16 G2X or Eclipse filter. Doc. 12533 at 6-7. Plaintiff Hyde has appealed this ruling. Docs.  
17 13465, 13480.

18 The Court denied Defendants' motion for the Tinlin bellwether trial, which involved  
19 a Recovery filter. Doc. 17401 at 7-10. The Tinlin case settled before trial.

20 The Court concluded for purposes of the Booker bellwether trial that evidence of  
21 cephalad migrations by a Recovery filter resulting in patient death was necessary for the  
22 jury to understand the issues that prompted creation and design of the next-generation G2  
23 filter, and thus was relevant to Plaintiff's design defect claims. Doc. 10323 at 4. In  
24 addition, because the Recovery filter was the predicate device for the G2 filter in  
25 Defendants' 510(k) submission to the FDA, and Defendants asserted to the FDA that the  
26 G2 was as safe and effective as the Recovery, the Court concluded that the safety and  
27 effectiveness of the Recovery filter was at issue. *Id.* The Court was concerned, however,  
28 that too heavy an emphasis on deaths caused by cephalad migration of the Recovery filter –

1 a kind of migration which did not occur in the G2 filter generally or the Booker case  
2 specifically – would result in unfair prejudice to Defendants that substantially outweighed  
3 the probative value of the evidence. *Id.* Defendants did not object during trial that  
4 Plaintiffs were over-emphasizing the death evidence.

5 The Court initially concluded for purposes of the Jones bellwether trial, which  
6 involved an Eclipse filter, that evidence of cephalad migration deaths by the Recovery filter  
7 was inadmissible because it was only marginally relevant to Plaintiff's claims and its  
8 marginal relevancy was substantially outweighed by the risk of unfair prejudice. *See Docs.*  
9 10819, 10920, 11041, 11113, 11256, 11302. This is because cephalad migration did not  
10 continue in any significant degree beyond the Recovery filter; cephalad migration deaths  
11 all occurred before the Recovery was taken off the market in late 2005; Ms. Jones did not  
12 receive her Eclipse filter until 2010; the Recovery-related deaths said nothing about three  
13 of Ms. Jones' four claims (strict liability design defect and the failure to warn claims); and  
14 instances of cephalad migration deaths were not substantially similar to complications  
15 experienced by Ms. Jones and therefore did not meet the Georgia standard for evidence on  
16 punitive damages. *Docs.* 10819, 11041.

17 The Court also found that deaths caused by a non-predicate device (the Recovery  
18 was not the predicate device for the Eclipse in Defendants' 510(k) submission), and by a  
19 form of migration that was eliminated years earlier, were of sufficiently limited probative  
20 value that their relevancy was substantially outweighed by the danger of unfair prejudice  
21 because the death evidence may prompt a jury decision based on emotion. *Id.* The Court  
22 further concluded that Plaintiff Jones would not be seriously hampered in her ability to  
23 prove Recovery filter complications, testing, and design when references to cephalad  
24 migration deaths are removed. *Doc.* 11041. As a result, the Court held that such references  
25 should be redacted from evidence presented during the Jones trial.

26 The Court balanced this concern with the competing concern that it would be unfair  
27 for Defendants to present statistics about the Recovery filter and not allow Plaintiffs to  
28 present competing evidence that included Recovery deaths. *See, e.g., Doc.* 11391 at 12.

1 Based on this concern, Plaintiffs argued at various points during the trial that Defendants  
2 had opened the door to presenting evidence about Recovery cephalad migration deaths.  
3 The Court repeatedly made fact-specific determinations on this point, holding that even  
4 though Defendants presented some evidence that made the Recovery evidence more  
5 relevant, the danger of unfair prejudice continued to substantially outweigh the probative  
6 value of the cephalad migration death evidence. *See* Docs. 11113, 11302; *see also* Doc.  
7 11409 at 94-96.

8 The Court concluded for purposes of the Hyde bellwether trial, which involved  
9 either a G2X or Eclipse filter, that evidence of Recovery filter cephalad migration deaths  
10 should be excluded under Rule 403 for the reasons identified in the Jones bellwether trial.  
11 Doc. 12533 at 6-7. The Court concluded that this evidence had marginal relevance to  
12 Plaintiff's claims because Ms. Hyde received either a G2X or Eclipse filter, two or three  
13 generations after the Recovery filter; Ms. Hyde did not receive her filter until 2011, more  
14 than five years after cephalad migration deaths stopped when the Recovery was taken off  
15 the market; the deaths did not show that G2X or Eclipse filters – which did not cause  
16 cephalad migration deaths – had design defects when they left Defendants' control; nor did  
17 the cephalad migration deaths, which were eliminated by design changes in the G2, shed  
18 light on Defendants' state of mind when designing and marketing the G2X and Eclipse  
19 filters. *Id.* at 7.

20 The Court concluded for purposes of the Tinlin bellwether trial, which involved a  
21 Recovery filter, that Recovery deaths and Defendants' knowledge of those deaths were  
22 relevant to Plaintiffs' design defect claim under Wisconsin law because they went directly  
23 to the Recovery's foreseeable risks of harm and whether it was unreasonably dangerous.  
24 Doc. 17401 at 7-8. The Court also concluded that the Recovery death evidence was  
25 relevant to Plaintiffs' failure to warn and concealment claims because it was probative on  
26 the causation issue – that is, whether her treating physician would have selected a different  
27 filter for Ms. Tinlin had he been warned about the Recovery's true risks, as Plaintiffs  
28 describe them. *Id.* at 8. In addition, because this evidence would be used to impeach expert

1 testimony from Defendants that the Recovery filter was safe and effective, the Court  
2 concluded that substantial similarity was not required. *Id.* at 8-9. The Court further  
3 concluded that the death evidence was relevant to Bard's state of mind and to show the  
4 reprehensibility of its alleged conduct for purposes of punitive damages. *Id.* at 9-10. The  
5 Court reached a different conclusion in the Jones and Hyde cases because cephalad  
6 migration deaths stopped when the Recovery was taken off the market in 2005, and the  
7 deaths shed little light on Defendants' state of mind when marketing different, improved  
8 filters years later. *Id.* at 9 n.4. As noted, the Tinlin case settled before trial.

9 **d. SNF Evidence.**

10 Plaintiffs sought to exclude evidence of complications associated with the SNF,  
11 claiming that they were barred from conducting relevant discovery into the design and  
12 testing of the SNF under CMO 10. Doc. 10487; *see* Doc. 1319. The Court denied  
13 Plaintiffs' request. Doc. 10489. The Court did not agree that Plaintiffs were foreclosed  
14 from obtaining relevant evidence for rebuttal. The Court foreclosed this discovery because  
15 Plaintiffs did not contend that the SNF was defective. *Id.* at 2. Plaintiffs also had rebuttal  
16 evidence showing that reported failure rates for SNF were lower than Recovery and G2  
17 failure rates. *Id.* The Court ultimately concluded it would not preclude Defendants from  
18 presenting its SNF evidence on the basis of a discovery ruling and permitted Plaintiffs to  
19 make appropriate evidentiary objections at trial. *Id.* at 3.

20 **e. Use of Testimony of Withdrawn Experts.**

21 Defendants sought to preclude Plaintiffs' use at trial of the depositions of three  
22 defense experts – Drs. Moritz, Rogers, and Stein – who originally were retained by Bard  
23 but were later withdrawn in some or all cases. Doc. 10255 at 2. The Court denied the  
24 request in part. Doc. 10382. The Court found that Defendants failed to show that the  
25 depositions of these experts were inadmissible on hearsay grounds, but agreed that it would  
26 be unfairly prejudicial under Rule 403 to disclose to the jury that the experts originally  
27 were retained by Bard. *Id.* at 2-3. The Court therefore concluded that Plaintiffs could use  
28 portions of the experts' depositions that support Plaintiffs' claims, but could not disclose

1 to the jury that the experts originally were retained by Bard. *Id.* at 3. The Court was  
2 concerned about the presentation of cumulative evidence, and therefore required Plaintiffs  
3 to show that no other expert of similar qualifications was available or that the unavailable  
4 expert had some unique testimony to contribute, before the deposition of any withdrawn  
5 expert could be used at trial. *Id.* at 3-4.

6 **f. Other Motion in Limine Rulings.**

7 Other motion in limine (“MIL”) rulings may be useful to the receiving courts. *See*  
8 Docs. 10075, 10235, 10258, 10947. The courts are referred to the following motions and  
9 orders to assist in preparing for trial:<sup>5</sup>

- 11 • **Parties’ Joint Stipulation on MILs in Booker:** The Court, on stipulation of the  
12 parties, excluded evidence concerning several case-specific issues in the Booker  
13 bellwether trial, as well as a few general issues, including: Bard’s 1994 criminal  
14 conviction; other lawsuits or claims against Bard; advertising by Plaintiff’s  
15 counsel; Plaintiff’s counsel specializing in personal injury or products liability  
16 litigation; contingency fee agreements; and advertising by any counsel  
17 nationally for IVC filter cases. Doc. 10235.
- 18 • **Defendants’ MIL 1 in Booker:** The Court permitted evidence and testimony  
19 concerning Recovery complications. Doc. 10258 at 1-5; *see* Doc. 10819 (Jones).  
20 As noted above, the Court permitted evidence and testimony concerning  
21 Recovery filter cephalad migration deaths in the Booker bellwether trial  
22 involving a G2 filter (Doc. 10323 at 4), but excluded such evidence in the trials  
23 involving a G2X or Eclipse filter (Docs. 10819, 10920, 11041).
- 24 • **Defendants’ MIL 2 in Booker:** The Court permitted evidence and testimony  
25 relating to the development of the Recovery filter. Doc. 10258 at 5-6; *see*  
26 Doc. 10819 at 2-3 (Jones).
- 27 • **Defendants’ MIL 4 in Booker:** The Court excluded evidence and testimony  
28 concerning a photograph of Bard employee Michael Randall making an  
offensive gesture. Doc. 10075 at 1-2.
- **Defendants’ MIL 5 in Booker:** The Court permitted Plaintiff’s expert  
Dr. Thomas Kinney to be called as a fact witness, but prohibited him from  
testifying regarding his prior work for Bard as an expert witness in two prior  
IVC filter cases or as a paid consultant to Bard. Docs. 10075 at 2-3, 10323 at 4.

---

<sup>5</sup> The Court also ruled on the parties’ MILs concerning several case-specific issues.  
*See* Docs. 10075 (Plaintiff’s MIL 12 in Booker), 10258 (Plaintiff’s’ MILs 6 and 13 in  
Booker), 10947 (Defendants’ MIL 1 and Plaintiff’s MILs 1-4 and 7 in Jones), 12533  
(Plaintiff’s MIL 3 in Hyde), 17285 (Plaintiff’s MIL 1 in Tinlin), 17401 (Plaintiff’s MILs  
2, 3, and 6 in Tinlin).



- 1 • **Plaintiff's MIL 2 in Booker:** The Court reserved ruling until trial on evidence  
2 and testimony regarding the nature of Bard's business, including the nature,  
3 quality, and usefulness of its products, the conscientiousness of its employees,  
4 and references to its mission statement. Doc. 10075 at 3-4.
- 5 • **Plaintiff's MIL 3 in Booker:** The Court permitted evidence and testimony  
6 concerning the benefits of IVC filters, including testimony describing Bard  
7 filters as "lifesaving" devices. Doc. 10258 at 8.
- 8 • **Plaintiff's MIL 4 in Booker:** The Court permitted evidence and testimony that  
9 IVC filters, including Bard's filters, are within the standard of care for the  
10 medical treatment of pulmonary embolism. Doc. 10258 at 8-9. Defendants  
11 agreed to not characterize IVC filters as the "gold standard" for the treatment of  
12 pulmonary embolisms. *Id.* at 8.
- 13 • **Plaintiff's MIL 5 in Booker:** The Court denied as moot the motion to exclude  
14 evidence and argument relating to failure rates, complication rates, percentages,  
15 or comparative analysis of any injuries that were not produced to Plaintiffs  
16 during discovery, as all such information was produced. Doc. 10075 at 4.
- 17 • **Plaintiff's MIL 7 in Booker:** The Court excluded evidence and argument  
18 relating to prior judicial opinions about Plaintiffs' experts, including the number  
19 of times their testimony has been precluded in other cases. *Id.*
- 20 • **Plaintiff's MIL 8 in Booker:** The Court excluded evidence and argument that  
21 a verdict against Defendants will have an adverse impact on the medical  
22 community, future medical device research or costs, and the availability of  
23 medical care. *Id.* at 4-5.
- 24 • **Plaintiff's MIL 9 in Booker:** The Court deferred ruling on the relevance of  
25 statements or lack of statements from medical societies, including the Society of  
26 Interventional Radiologists ("SIR"), until trial. Doc. 10258 at 14-18. The Court  
27 ultimately admitted this evidence in both the Booker and Jones bellwether trials.
- 28 • **Plaintiff's MIL 10 in Booker:** The Court excluded evidence and testimony that  
Bard needed FDA consent to add warnings to its labels, send warning letters to  
physicians and patients, or recall its filters. *Id.* at 18-19. The Court permitted  
evidence and argument explaining the reasons why Bard filters were not  
recalled, FDA's potential involvement in any recall effort, and the fact that  
warnings about failure rates and increased risks could not be based on MDR and  
MAUDE data alone. *Id.*
- **Plaintiff's MIL 11 in Booker:** The Court permitted evidence and argument  
relating to the informed consent form signed by Plaintiff prior to insertion of the  
IVC filter, even though the form is not specific to IVC filters or Bard filters.  
Doc. 10075 at 5-6.
- **Plaintiff's MIL 14 in Booker:** The Court reserved ruling until trial on evidence  
and argument relating to background information and personal traits of Bard  
employees and witnesses. *Id.* at 7.
- **Plaintiff's MIL 6 in Jones:** The Court permitted evidence and testimony  
concerning whether a party's expert had been retained by the same attorneys in  
other litigation. Doc. 10947 at 8-9.

- **Plaintiff's MIL 5 in Jones:** The Court excluded evidence and testimony that Bard employees or their relatives have received Bard IVC filter implants. *Id.* at 9-10.
- **Defendants' MIL 2 in Jones:** The Court excluded evidence and testimony of other lawsuits against Bard. *Id.* at 11.
- **Plaintiff's MILs 4 and 5 in Hyde:** The Court permitted evidence and testimony concerning Bard's Instructions for Use ("IFU") and SIR Guidelines. Doc. 12507.
- **Plaintiff's MIL 2 in Hyde:** The Court permitted evidence and testimony concerning "The Surgeon General's Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism." Doc. 12533 at 4-6.
- **Defendants' MIL 3 in Hyde:** The Court permitted evidence and testimony that Bard's SNF is a reasonable alternative design. *Id.* at 7.
- **Defendants' MIL 4 in Hyde:** The Court excluded testimony from Dr. Muehrcke about his personal feelings of betrayal and his moral and ethical issues with Bard's conduct. *Id.* at 7-8.
- **Defendants' MIL 6 in Hyde:** The Court permitted evidence and testimony regarding informed consent. *Id.* at 8-9.
- **Plaintiff's MIL 4 in Tinlin:** The Court reserved ruling until trial on evidence and argument relating to a chart created by Defendants from their internal TrackWise database regarding reporting rates of IVC filter complications. Doc. 17401 at 5.
- **Plaintiff's MIL 5 in Tinlin:** The Court permitted evidence and testimony concerning a chart comparing the sales of the permanent SNF with those of retrievable filters between 2002 and 2016. *Id.* at 5-6.
- **Defendants' MIL 3 in Tinlin:** The Court permitted evidence and testimony concerning the Recovery Filter Crisis Communications Plan that Bard had prepared in 2004 to help manage damaging media coverage about a Recovery migration death. *Id.* at 11-12.
- **Defendants' MIL 4 in Tinlin:** The Court excluded evidence and testimony concerning Dr. Muehrcke's untimely disclosed opinion that one of his patients died from cardiac tamponade caused by a fractured strut that had embolized to her heart. *Id.* at 12-13.

///

///

///

///

///

1                   **6.     Deposition Designation Rulings.**

2                   The Court has ruled on numerous objections to deposition designations for trial and  
3 refers the transferor courts to the following orders:<sup>6</sup>

4

5 <b>Deponent</b>	6 <b>Depo. Date</b>	7 <b>Doc. No(s).</b>
8                   Bill Altonaga	9                   10/22/2013	10                  10497, 10922
11                  Christine Brauer	12                  05/23/2014 13                  08/02/2017	14                  10922, 15                  10922
16                  David Ciavarella	17                  11/12/2013	18                  10403
19                  Gary Cohen	20                  01/25/2017	21                  10438
22                  Robert Cortelezzi	23                  11/11/2016	24                  10438, 11064
25                  Len DeCant	26                  05/24/2016	27                  10438, 11080
28                  John DeFord	06/02/2016	10524, 11080
Mary Edwards	01/20/2014	10438
Robert Ferrara	04/17/2017	10438
Chris Ganser	10/11/2016	10438, 11073
Jason Greer	08/11/2014	10438, 10922
Janet Hudnall	11/01/2013	10403
Brian Hudson	01/17/2014	10403
John Lehmann	08/07/2014	10922
William Little	07/27/2016	10438, 11064
John McDermott	02/05/2014	10438

26

---

27

28                   <sup>6</sup> In addition to the depositions identified in the table above, the Court ruled on numerous objections to case-specific deposition designations for trial.

<b>Deponent</b>	<b>Depo. Date</b>	<b>Doc. No(s).</b>
Patrick McDonald	07/29/2016	10486, 11064
Mark Moritz	07/18/2017	10922
Daniel Orms	08/16/2016	10403, 11073
Abithal Raji-Kubba	07/18/2016	11064
Gin Schulz	01/30/2014	10403
Christopher Smith	08/03/2017	11073
William Stavropoulos	02/01/2017	10524
Jack Sullivan	11/03/2016 09/16/2016	10486, 11080
Melanie Sussman	04/07/2017	11073
Mehdi Syed	03/02/2018	11313
Scott Trerotola	01/20/2017	10524
Douglas Uelmen	10/04/2013	10403, 11080
Carol Vierling	05/11/2016	10486, 11073
Mark Wilson	01/31/2017	10922
Natalie Wong	10/18/2016	10403
John Worland	03/16/2011	17582

## **7. Subject Matter Jurisdiction Ruling.**

The parties identified cases in the MDL for which federal subject matter jurisdiction does not exist. Docs. 20210, 21410, 21552. No federal question jurisdiction exists under 28 U.S.C. § 1331 because the master complaint asserts no federal claim and the state law claims alleged in the complaint do not depend on the resolution of a federal law question. Doc. 364 ¶¶ 166-349. For purposes of diversity jurisdiction under 28 U.S.C. § 1332,

1 Defendant C. R. Bard, Inc. is a citizen of New Jersey and Defendant Bard Peripheral  
2 Vascular, Inc. is a citizen of Arizona. *See id.* ¶¶ 11-12. Thus, complete diversity between  
3 the parties does not exist in any case where each Defendant is a named party and Plaintiff  
4 is a resident of either Arizona or New Jersey. *See* Doc. 20210-1.

5 Plaintiffs in most of the cases without subject matter jurisdiction agreed to a  
6 dismissal without prejudice. *See id.* Plaintiffs in other cases opposed dismissal, but  
7 provided no reason why the cases should not be dismissed. *See id.* The Court dismissed  
8 without prejudice multiple cases for lack of subject matter jurisdiction. *See* Docs. 20667,  
9 21461, 21579. Some of these cases may be refiled in state court. *See* Doc. 20210-1.

10 **I. Further Proceedings in Remanded or Transferred Cases.**

11 **1. General Discovery.**

12 Because all general fact and expert discovery has been completed in this MDL, the  
13 courts receiving these cases need not be concerned with facilitating general expert,  
14 corporate, and third-party discovery. This observation is not meant to restrict the power of  
15 transferee courts for good cause or in the interest of justice to address issues that may be  
16 unique and relevant in a remanded or transferred case.

17 **2. Case-Specific Discovery and Trial Preparation.**

18 According to the parties, the status of the remaining discovery and other pretrial  
19 issues for the cases being transferred, and the estimated time needed to resolve such issues  
20 and make the cases ready for trial, will be determined after transfer. Final trial preparation  
21 in the bellwether trials was governed by certain Court orders. *See* Docs. 8871, 10323,  
22 10587, 11011, 11320, 11321, 11659, 11871, 12061, 12853, 12971.

23 **J. Documents to Be Sent to Transferee Courts.**

24 The Court has concluded that the cases listed on Schedule A should be transferred  
25 to appropriate districts pursuant to 28 U.S.C. § 1404(a). Upon receipt of this transfer order,  
26 the Clerk for this District shall issue a letter to the transferee courts, via email, setting out  
27 the process for transferring the case. The letter and certified copy of this transfer order will  
28 be sent to the transferee courts' email addresses.

1 The parties have submitted a stipulated designation of record for transferred cases.  
2 *See* Doc. 21553-4; *see also* Doc. 19444-1. Upon receipt of this transfer order, the Clerk of  
3 this District shall transmit to the transferee court the following: (1) a copy of the individual  
4 docket sheet for the transferred action, (2) a copy of the master docket sheet in this MDL,  
5 and (3) the record designated by the parties.

6 If a party believes that the docket sheet for a particular case being transferred is not  
7 correct, a party to that case may, with notice to all other parties in the case, file with the  
8 transferee court a designation amending the record. Upon receiving such designation, the  
9 transferee court may make any needed changes to the docket. If the docket is revised to  
10 include additional documents, the parties should provide those documents to the transferee  
11 court.


12 **III. Conclusion.**

13 Pursuant to 28 U.S.C. § 1404(a), the Clerk of this District is directed to transfer the  
14 cases listed on Schedule A to appropriate districts for further proceedings.

15 The Clerk of this District is directed to unconsolidate two cases from the MDL:  
16 *Bernadette McBride v. C. R. Bard, Inc.*, No. 2:19-cv-02819, and *Lonnie Easton v. C. R.*  
17 *Bard, Inc.*, No. 2:19-cv-04274. These cases will remain in the District of Arizona and be  
18 assigned to the undersigned judge.

19 **IT IS SO ORDERED.**

20 Dated this 10th day of September, 2020.

21  
22  
23 

24 David G. Campbell  
25 Senior United States District Judge  
26  
27  
28

***In re Bard IVC Filters Products Liability Litigation, No. MDL 15-02641***

**TRANSFER ORDER (FOURTH)  
Schedule A – Direct-Filed Cases to Be Transferred  
(September 10, 2020)**

<b>Case Caption</b>	<b>Case Number</b>	<b>Transferee District</b>
David L. Ball v. C.R. Bard, Inc.	2:17-cv-01681	Ala. N.D.
Rickey Scott v. C.R. Bard, Inc.	2:19-cv-04063	Ala. S.D.
Nicholas Blake Norton v. C.R. Bard, Inc.	2:17-cv-01900	Ala. S.D.
Rita Rundel v. C.R. Bard, Inc.	2:19-cv-04235	Ark. E.D.
Scottie C. Wolford v. C.R. Bard, Inc.	2:19-cv-01250	Ark. W.D.
Shirely Ann Howard v. C.R. Bard, Inc.	2:17-cv-01734	Ark. W.D.
Chleora Kay Bergquist v. C.R. Bard, Inc.	2:19-cv-03942	Cal. N.D.
Alvis Edwards Deeds v. C.R. Bard, Inc.	2:19-cv-04272	Colo.
Lisa Monique Wilkins v. C.R. Bard, Inc.	2:19-cv-03932	DC
Nicole Subryan v. C.R. Bard, Inc.	2:17-cv-01729	DC
Debra Ann Skinner v. C.R. Bard, Inc.	2:17-cv-02409	DC
Sandra L. Olio v. C.R. Bard, Inc.	2:19-cv-03739	Fla M.D.
Deborah St. John, Personal Representative for Sloan Christiansen v. C. R. Bard, Inc.	2:19-cv-03951	Fla. M.D.
Sherry Lynn Black Goodrow v. C.R. Bard, Inc.	2:18-cv-00406	Fla. M.D.
Robert Lee Felder v. C.R. Bard, Inc.	2:19-cv-03728	Fla. M.D.
Tammy Lynn Young v. C.R. Bard, Inc.	2:19-cv-03989	Fla. M.D.
Ross A. Grey v. C.R. Bard, Inc.	2:17-cv-04030	Fla. M.D.
Kenneth Ivan Holbrook v. C.R. Bard, Inc.	2:19-cv-01234	Fla. M.D.
Iarzella Marthe Dennard v. C.R. Bard, Inc.	2:19-cv-01539	Fla. M.D.
James Wesley Jordan v. C.R. Bard, Inc.	2:19-cv-04110	Fla. S.D.
Edmund Lucarelli, Jr. v. C.R. Bard, Inc.	2:18-cv-03675	Fla. S.D.
Prudence Peterson v. C.R. Bard, Inc.	2:18-cv-02090	Fla. S.D.
Theresa Melvin Mounsey v. C.R. Bard, Inc.	2:17-cv-02415	Fla. S.D.
Carmen Delia Burgos v. C.R. Bard, Inc.	2:19-cv-02898	Fla. S.D.
Steven Rogers v. C.R. Bard, Inc.	2:17-cv-04083	Ga. N.D.

***In re Bard IVC Filters Products Liability Litigation, No. MDL 15-02641***

**TRANSFER ORDER (FOURTH)  
Schedule A – Direct-Filed Cases to Be Transferred  
(September 10, 2020)**

<b>Case Caption</b>	<b>Case Number</b>	<b>Transferee District</b>
Anthony Jackson v. C.R. Bard, Inc.	2:19-cv-01467	Ga. N.D.
Mark Daniel Dills v. C.R. Bard, Inc.	2:19-cv-01512	Ga. N.D.
Lauren Kent v. C.R. Bard, Inc.	2:19-cv-04076	Ga. S.D.
Nancy Harmon v. C.R. Bard, Inc.	2:19-cv-00721	Ga. S.D.
Linda Jenkins v. C.R. Bard, Inc.	2:18-cv-03935	Iowa N.D.
Troy McKittrick v. C.R. Bard, Inc.	2:19-cv-03231	Ill. C.D.
Karen Jandula v. C.R. Bard, Inc.	2:19-cv-02305	Ill. N.D.
Richard Jason West v. C. R. Bard, Inc.	2:19-cv-03303	Ill. N.D.
Delores Watson v. C.R. Bard, Inc.	2:17-cv-03990	Ind. S.D.
Adam Kyle Fisher v. C.R. Bard, Inc.	2:17-cv-02805	Ind. S.D.
Joanie Hansford, as Administrator of the Estate of Michele Hansford v. C. R. Bard, Inc.	2:19-cv-01526	Kan.
Kristi G. Bailey v. C.R. Bard, Inc.	2:17-cv-04029	Ky. E.D.
Phyllis Rae Steinhoff v. C.R. Bard, Inc.	2:19-cv-03965	Ky. W.D.
Reba Carter v. C.R. Bard, Inc.	2:19-cv-01457	Ky. W.D.
Michael J. Palmer v. C.R. Bard, Inc.	2:19-cv-04227	La. E.D.
Wayne Francis Melancon, Sr. v. C.R. Bard, Inc.	2:17-cv-01733	La. E.D.
Marc J. Houle v. C.R. Bard, Inc.	2:17-cv-01705	Mass.
Kandy Carpenter v. C.R. Bard, Inc.	2:19-cv-01525	Mich. E.D.
Thomas Orest v. C.R. Bard, Inc.	2:17-cv-04095	Minn.
Naomi Gardner v. C.R. Bard, Inc.	2:19-cv-04294	Mo. W.D.
Penni Hendrickson v. C.R. Bard, Inc.	2:19-cv-04073	Mo. W.D.
Kathy Lucille Spencer v. C.R. Bard, Inc.	2:19-cv-03944	Mo. W.D.
Lisa Johnson v. C.R. Bard, Inc.	2:19-cv-02001	Mo. W.D.
Sarah Rosalie Mobley v. C.R. Bard, Inc.	2:17-cv-02239	Mo. W.D.
Sandra Risner v. C.R. Bard, Inc.	2:19-cv-02136	Miss. N.D.



**TRANSFER ORDER (FOURTH)**  
**Schedule A – Direct-Filed Cases to Be Transferred**  
**(September 10, 2020)**

<b>Case Caption</b>	<b>Case Number</b>	<b>Transferee District</b>
Shari Elaine Maresh v. C.R. Bard, Inc.	2:19-cv-01632	N.C. E.D.
Kristine Louise Allsbury v. C.R. Bard, Inc.	2:19-cv-03781	N.C. M.D.
Jeremy Gates v. C.R. Bard, Inc.	2:19-cv-01498	N.C. W.D.
Nichols R. Garon v. C.R. Bard, Inc.	2:19-cv-01238	N.H.
Buntricia Bastian v. C.R. Bard, Inc.	2:19-cv-00369	Nev.
Michael Campobasso v. C.R. Bard, Inc.	2:19-cv-01575	Nev.
Carolyn Sue Cuyler v. C.R. Bard, Inc.	2:17-cv-01704	Nev.
Kevin Carenza v. C.R. Bard, Inc.	2:19-cv-03979	N.Y. E.D.
Clyde Solomon v. C.R. Bard, Inc.	2:19-cv-01466	N.Y. E.D.
Christopher Beasock v. C.R. Bard, Inc.	2:19-cv-01465	N.Y. E.D.
Jimmy Reed Dillard, Jr. v. C.R. Bard, Inc.	2:19-cv-04273	N.Y. N.D.
Marie Spencer v. C.R. Bard, Inc.	2:19-cv-04053	N.Y. S.D.
Agnes Roberts v. C.R. Bard, Inc.	2:17-cv-00138	N.Y. S.D.
Gloria Cleveland v. C.R. Bard, Inc.	2:19-cv-04179	N.Y. W.D.
Deborah S. Hamby v. C.R. Bard, Inc.	2:19-cv-01449	N.Y. W.D.
Kimberly Roberts v. C.R. Bard, Inc.	2:18-cv-02828	Ohio N.D.
Sherrie Lynn Butler v. C.R. Bard, Inc.	2:17-cv-01142	Ohio N.D.
Jeramey Kohar v. C.R. Bard, Inc.	2:19-cv-01780	Ohio S.D.
Edward Schaab v. C.R. Bard, Inc.	2:19-cv-02133	Ohio S.D.
Keyon Phillip Williams v. C.R. Bard, Inc.	2:17-cv-00606	Ohio S.D.
Keith L. Bryant v. C.R. Bard, Inc.	2:17-cv-01703	Ohio S.D.
Jessica Jean Johnson v. C.R. Bard, Inc.	2:17-cv-01706	Ohio S.D.
Adlen June Silas v. C.R. Bard, Inc.	2:17-cv-01707	Ohio S.D.
Tina M. Savage v. C.R. Bard, Inc.	2:17-cv-01731	Ohio S.D.
William Dennie Evans, III v. C.R. Bard, Inc.	2:17-cv-01816	Ohio S.D.
Lillie Elizabeth Wilburn v. C.R. Bard, Inc.	2:17-cv-02555	Ohio S.D.

***In re Bard IVC Filters Products Liability Litigation, No. MDL 15-02641***

**TRANSFER ORDER (FOURTH)  
Schedule A – Direct-Filed Cases to Be Transferred  
(September 10, 2020)**

<b>Case Caption</b>	<b>Case Number</b>	<b>Transferee District</b>
Rudy Headley v. C.R. Bard, Inc.	2:19-cv-01497	Okla. W.D.
William Murphy v. C.R. Bard, Inc.	2:19-cv-04233	Pa. E.D.
Douglas J. Dohan v. C.R. Bard, Inc.	2:19-cv-04069	Pa. E.D.
Justin Ubel v. C.R. Bard, Inc.	2:19-cv-02073	Pa. E.D.
Rachel Evans v. C.R. Bard, Inc.	2:19-cv-04225	Pa. M.D.
Clinton Elliott Hufnagle v. C.R. Bard, Inc.	2:19-cv-03244	Pa. M.D.
Jeanette McFarland v. C.R. Bard, Inc.	2:19-cv-01511	Pa. W.D.
James O. Roberts v. C.R. Bard, Inc.	2:19-cv-03625	S.C.
Charles Ronald Finch v. C.R. Bard, Inc.	2:19-cv-01533	S.C.
Bruce R. Cunningham v. C.R. Bard, Inc.	2:19-cv-01236	Tex. E.D.
Franky Williams v. C.R. Bard, Inc.	2:19-cv-04070	Tex. N.D.
Bryon Kelly Rieken v. C.R. Bard, Inc.	2:19-cv-04061	Tex. N.D.
Dale Anthony Hall v. C.R. Bard, Inc.	2:19-cv-04058	Tex. N.D.
Alejandro G. Santana v. C.R. Bard, Inc.	2:18-cv-02264	Tex. S.D.
James Shutter v. C.R. Bard, Inc.	2:19-cv-03345	Tex. S.D.
Melissa Jane Sepeda v. C.R. Bard, Inc.	2:18-cv-01585	Tex. S.D.
Edward Lee Smith v. C.R. Bard, Inc.	2:19-cv-01630	Tex. W.D.
Charles Henry Wand v. C.R. Bard, Inc.	2:19-cv-02098	Tex. W.D.
Robert John Allsopp v. C.R. Bard, Inc.	2:19-cv-04049	Tex. W.D.
Peggy Sue Clarke v. C.R. Bard, Inc.	2:19-cv-03727	Va. E.D.
David S. Breeden v. C.R. Bard, Inc.	2:19-cv-01535	Va. E.D.
Benjamin Kwame Quarmon v. C.R. Bard, Inc.	2:17-cv-00335	Va. E.D.
Johnie W. Dalton v. C.R. Bard, Inc.	2:19-cv-04268	Va. W.D.
Norman E. Rose v. C.R. Bard, Inc.	2:19-cv-04083	Wa. W.D.
Kelly Kuester v. C.R. Bard, Inc.	2:19-cv-02904	Wis. E.D.
Jody Marie Snyder v. C.R. Bard, Inc.	2:17-cv-03272	Wis. W.D.

***In re Bard IVC Filters Products Liability Litigation*, No. MDL 15-02641**

**TRANSFER ORDER (FOURTH)**  
**Schedule A – Direct-Filed Cases to Be Transferred**  
**(September 10, 2020)**

<b>Case Caption</b>	<b>Case Number</b>	<b>Transferee District</b>
Chasity Adkins v. C.R. Bard, Inc.	2:19-cv-04261	W.V. S.D.
Angela Rhodes v. C.R. Bard, Inc.	2:19-cv-02135	W.V. S.D.

**TRANSFER ORDER (FOURTH)**

**Exhibit 1 – MDL Orders**

<b>CASE MANAGEMENT ORDERS (CMOs)</b>		
<b>Date Filed</b>	<b>Doc. No.</b>	<b>Docket Text</b>
10/30/2015	248	CMO 1 re Leadership Counsel Appointments
11/16/2016	4016	Amended CMO 1 re Leadership Counsel Appointments
03/21/2017	5285	Second Amended CMO 1 re Plaintiff Leadership Team
02/04/2019	15098	Third Amended CMO 1 re Plaintiff Leadership Team
10/30/2015	249	CMO 2 re Setting Deadlines, First Phase of Discovery
12/01/2015	314	CMO 3 re Non-waiver Order Pursuant to Rule 502(d)
12/17/2015	363	CMO 4 re Master Complaint, Responsive Pleadings, Short Form Complaint, Waiver, and Answer
3/17/2016	1108	Amended CMO 4 re Master Complaint, Responsive Pleadings, Short Form Complaint, Waiver, and Answer
4/20/2016	1485	Second Amended CMO 4 re Master Complaint, Responsive Pleadings, Short Form Complaint, Waiver, and Answer
12/17/2015	365	CMO 5 re Plaintiff and Defendant Profile Forms
03/03/2016	927	Amended CMO 5 re Plaintiff and Defendant Profile Forms
12/18/2015	372	CMO 6 re Rules to Establishing Common Benefit Fee
01/05/2016	401	CMO 7 re Stipulations Concerning Redactions
02/02/2016	519	CMO 8 re Second Phase of Discovery
03/31/2016	1259	CMO 9 re ESI and production protocol
04/01/2016	1319	CMO 10 re Second Phase Discovery, Bellwether, ESI, FDA, Deposition, and Privilege Log
05/05/2016	1662	CMO 11 re Bellwether Selection Process
05/05/2016	1663	CMO 12 re Joint Record Collection
06/21/2016	2238	CMO 13 re ESI, FDA Warning Letter and Designations
06/21/2016	2239	CMO 14 re Deposition Protocols

***In re Bard IVC Filters Products Liability Litigation*, No. MDL 15-02641-PHX-DGC**

<b>CASE MANAGEMENT ORDERS (CMOs)</b>		
<b>Date Filed</b>	<b>Doc. No.</b>	<b>Docket Text</b>
08/25/2016	3214	CMO 15 re <i>Lexecon</i> Waivers, ESI Discovery, Multi-plaintiff Actions, and Deceased Plaintiffs
08/25/2016	3215	CMO 16 re Deadlines Related to Barraza
12/02/2016	4141	Amended CMO 16 re Deadlines Related to Barraza
09/14/2016	3372	CMO 17 re Protective Order and Expedited ESI Production
11/16/2016	4015	Amended CMO 17 re Protective Order and Redactions of Material from Expedited ESI Production
10/17/2016	3685	CMO 18 re Adjusted Discovery Schedule
12/13/2016	4311	CMO 19 re ESI and Bellwether Selection
12/22/2016	4335	CMO 20 re Discovery Deadlines for Discovery Group 1 and Bellwether Group 1
02/06/2017	4866	CMO 21 re Discovery Protocols for Discovery Group 1
02/17/2017	5007	CMO 22 re Setting Deadlines
05/05/2017	5770	CMO 23 re Expert Deposition Deadlines, Bellwether Case Selection, Preemption Motion for Summary Judgment, and Mature Cases
05/19/2017	5881	CMO 23 re Discovery Protocols for Bellwether Group 1
05/19/2017	5883	Amended CMO 24 re Discovery Protocols for Bellwether Group 1
06/06/2017	6227	CMO 25 re Bellwether Group 1 Amended Discovery Schedule
07/17/2017	6799	CMO 26 re Depositions of Dr. Henry and Dr. Altonaga, Communications among Plaintiffs' Experts, and Bellwether Trial Issues
10/10/2017	8113	CMO 27 re Privilege Issues, Bellwether Trial Schedule, Plaintiffs' Motion for Partial Summary Judgment, and Recusal Unnecessary
11/21/2017	8871	CMO 28 re Booker Bellwether Trial Schedule, and Mature Cases

***In re Bard IVC Filters Products Liability Litigation, No. MDL 15-02641-PHX-DGC***

<b>CASE MANAGEMENT ORDERS (CMOs)</b>		
<b>Date Filed</b>	<b>Doc. No.</b>	<b>Docket Text</b>
12/21/2017	9415	CMO 29 re Booker Bellwether Trial Schedule, Motion to Certify Appeal, and <i>Cisson</i> Motion Briefing
01/23/2018	9775	CMO 30 re Motions Hearings, Motions in Limine, and Punitive Damages in Booker
03/02/2018	10323	CMO 31 re Booker Trial
05/07/2018	11011	CMO 32 re Jones Trial
06/01/2018	11320	CMO 33 re Mulkey as Next Bellwether Selection, and Mulkey Trial Schedule
06/28/2018	11659	CMO 34 re Next 3 Bellwether Trials, Kruse Trial Schedule, Use of Dr. Kandarpa at Trial, Sixth Bellwether Tinlin, Disposition of SNF Cases, and Remand of Mature Cases
07/13/2018	11871	CMO 35 re September, November and May Bellwether Trials, and Hyde September Bellwether Trial Schedule
08/02/2018	12061	CMO 36 re Tinlin Bellwether Pre-trial Schedule
10/04/2018	12830	CMO 37 re Hyde Trial
10/05/2018	12853	CMO 38 re Future Bellwether Trials, February and May Bellwether Trials, Motion to Seal Trial Exhibits, Settlement Talks and Remand, and SNF Cases
10/16/2018	12971	CMO 39 re Tinlin Bellwether Case
11/08/2018	13329	CMO 40 re Mulkey Bellwether Trial
02/08/2019	15176	CMO 41 re Tinlin Trial, SNF Cases, Remand of Mature Cases, and Possible Settlement Procedures
03/21/2019	16343	CMO 42 re Tinlin Trial, SNF Cases, Duplicative Cases, Settlement Procedures and Remand or Transfer
05/02/2019	17494	CMO 43 re Tinlin Trial, Common Benefit Fund Fee and Expense Accounts, Closing Date for New Cases and Remand or Transfer, and SNF Cases
05/16/2020	17777	CMO 44 re Common Benefit Fund Accounts
05/31/2020	18079	CMO 45 re MDL closure

***In re Bard IVC Filters Products Liability Litigation, No. MDL 15-02641-PHX-DGC***

<b>CASE MANAGEMENT ORDERS (CMOs)</b>		
<b>Date Filed</b>	<b>Doc. No.</b>	<b>Docket Text</b>
03/27/2020	21480	CMO 46 re Common Benefit Fee and Cost Committee (Sealed Ex Parte Order)
06/29/2020	21528	Amended CMO 46 (Sealed Ex Parte Order)
07/16/2020	21540	CMO 47 re settlement status of cases and cases dismissed without prejudice

<b>DISCOVERY ORDERS</b>		
<b>Date Filed</b>	<b>Doc. No.</b>	<b>Docket Text</b>
10/30/2015	249	CMO 2 re Setting Deadlines, First Phase of Discovery
02/02/2016	519	CMO 8 re Second Phase of Discovery
03/31/2016	1259	CMO 9 re Electronically Stored Information and production protocol
04/01/2016	1319	CMO 10 re Second Phase Discovery, Bellwether, ESI, FDA, Deposition, and Privilege Log
05/05/2016	1663	CMO 12 re Joint Record Collection
06/21/2016	2238	CMO 13 re ESI, FDA Warning Letter and Designations
06/21/2016	2239	CMO 14 re Deposition Protocols
08/25/2016	3214	CMO 15 re <i>Lexecon</i> Waivers, ESI Discovery, Multi-plaintiff Actions, and Deceased Plaintiffs
08/29/2016	3272	Order re Deposition of Jim Beasley
09/06/2016	3312	Order re discovery disputes concerning Plaintiffs' communications with FDA
09/06/2016	3313	Order re Plaintiffs' communications with NBC or other media outlets and admissibility at trial
09/06/2016	3314	Order re Plaintiffs' third party funding arrangements
09/14/2016	3372	CMO 17 re Protective Order and Expedited ESI Production

***In re Bard IVC Filters Products Liability Litigation, No. MDL 15-02641-PHX-DGC***

<b>DISCOVERY ORDERS</b>		
<b>Date Filed</b>	<b>Doc. No.</b>	<b>Docket Text</b>
11/16/2016	4015	Amended CMO 17 re Protective Order and Redactions of Material from Expedited ESI Production
09/16/2016	3398	Order re ESI generated by foreign entities that sell filters abroad
10/17/2016	3685	CMO 18 re Adjusted Discovery Schedule
12/13/2016	4311	CMO 19 re ESI and Bellwether Selection
12/22/2016	4335	CMO 20 re Discovery Deadlines for Discovery Group 1 and Bellwether Group 1
12/24/2016	4339	Order re proposed depositions of and interrogatories to Plaintiffs' counsel
02/06/2017	4865	Order re discovery dispute on ex parte communications with treating physicians and depositions of treating physicians and sales representatives
02/06/2017	4866	CMO 21 re Discovery Protocols for Discovery Group 1
05/05/2017	5770	CMO 23 re Expert Deposition Deadlines, Bellwether Case Selection, Preemption Motion for Summary Judgment, and Mature Cases
05/19/2017	5881	CMO 23 re Discovery Protocols for Bellwether Group 1
05/19/2017	5883	Amended CMO 24 re Discovery Protocols for Bellwether Group 1
06/06/2017	6227	CMO 25 re Bellwether Group 1 Amended Discovery Schedule
07/17/2017	6799	CMO 26 re Depositions of Dr. Henry and Dr. Altonaga, Communications among Plaintiffs' Experts, and Bellwether Trial Issues



***In re Bard IVC Filters Products Liability Litigation, No. MDL 15-02641-PHX-DGC***

<b>DISCOVERY AND PRIVILEGE ORDERS</b>		
<b>Date Filed</b>	<b>Doc. No.</b>	<b>Docket Text</b>
12/01/2015	314	CMO 3 re Non-waiver Order Pursuant to Rule 502(d)
02/11/2016	699	Order re Motion for Protective Order concerning Dr. John Lehmann's December 15, 2004, report as protected work product
07/25/2016	2813	Order re Plaintiffs' Motion to Compel (Privilege Log Issues)
02/06/2017	4865	Order re discovery dispute on ex parte communications with treating physicians and depositions of treating physicians and sales representatives
07/17/2017	6799	CMO 26 re Depositions of Dr. Henry and Dr. Altonaga, Communications among Plaintiffs' Experts, and Bellwether Trial Issues
10/10/2017	8113	CMO 27 re Privilege Issues, Bellwether Trial Schedule, Plaintiffs' Motion for Partial Summary Judgment, and Recusal Unnecessary
10/20/2017	8315	Order that Plaintiffs need not produce the withheld expert communications or provide a privilege log on these communications to Defendants.

<b>DAUBERT ORDERS</b>		
<b>Date Filed</b>	<b>Doc. No.</b>	<b>Docket Text</b>
12/21/2017	9428	Order re Motion to Disqualify Plaintiffs' Expert Thomas Kinney, M.D.
12/21/2017	9432	Order re Motion to Disqualify Plaintiffs' Experts Drs. Resnick, Vogelzang, and Desai
12/22/2017	9433	Order re Motion to Exclude Plaintiffs' Experts Drs. Parisian and Kessler
12/22/2017	9434	Order re Motion to Exclude Plaintiffs' Experts Drs. Kinney, Roberts, and Kalva
01/22/2018	9770	Order re Motion to Exclude Plaintiffs' Expert Dr. Eisenberg
01/22/2018	9771	Order re Motion to Exclude Plaintiffs' Expert Dr. Muehrcke

***In re Bard IVC Filters Products Liability Litigation, No. MDL 15-02641-PHX-DGC***

<b>DAUBERT ORDERS</b>		
<b>Date Filed</b>	<b>Doc. No.</b>	<b>Docket Text</b>
01/22/2018	9772	Order re Motion to Exclude Plaintiffs' Expert Dr. Hurst
01/22/2018	9773	Order re Motion to Exclude Plaintiffs' Expert Dr. Betensky
02/06/2018	9991	Order re Motion to Exclude Bard's Expert Dr. Grassi
02/08/2018	10051	Order re Motion to Exclude Plaintiffs' Expert Dr. McMeeking
02/08/2018	10052	Order re Motion to Exclude Plaintiffs' Expert Dr. Ritchie
02/12/2018	10072	Order re Motion to Exclude Plaintiffs' Experts Drs. Garcia and Streiff
02/21/2018	10230	Order re Motion to Exclude Bard's Experts Drs. Grassi and Morris
02/21/2018	10231	Order re Motion to Exclude Bard's Expert Dr. Morris
04/16/2019	16992	Order re Motion to Exclude Plaintiffs' Expert Dr. McMeeking
04/23/2019	17285	Order re Motion to Exclude Bard's Expert Dr. Morris

<b>MOTIONS IN LIMINE ORDERS</b>		
<b>Date Filed</b>	<b>Doc. No.</b>	<b>Docket Text</b>
01/23/2018	9775	CMO 30 re Motions Hearings, Motions in Limine, and Punitive Damages in Booker
01/26/2018	9861	Joint Stipulation re prohibiting raising certain issues in the presence of the jury for Booker Bellwether case
01/29/2018	9881	Order re admissibility of (1) pre-market clearance of Bard IVC filters by FDA and (2) the lack of FDA Enforcement Action against Bard
02/15/2018	10075	Order re Motions in Limine re Photographs of Mike Randall, Dr. Kinney work for Bard, Benevolent Activities, Evidence Not Produced in Complaint Files, Prior Judicial Opinions, Adverse Impact of a Plaintiff's Verdict, Informed Consent

***In re Bard IVC Filters Products Liability Litigation, No. MDL 15-02641-PHX-DGC***

<b>MOTIONS IN LIMINE ORDERS</b>		
<b>Date Filed</b>	<b>Doc. No.</b>	<b>Docket Text</b>
		Form, Dr. Kang Social Media Posts, Personal Traits of Employees and Witnesses for Booker Bellwether case
02/22/2018	10235	Order re Parties' Joint Stipulation re prohibiting raising certain issues in the presence of the jury for Booker Bellwether case
03/01/2018	10258	Order re Motions in Limine re Recovery® Filter Complications, Recovery® Filter Development, FDA Warning Letter, IVC Filter as Lifesaving Devices, IVC filters are Gold Standard, Nonparties at Fault, Statements from Associations and Other Groups, FDA Consent for Warnings or Recalls for Booker Bellwether case
03/09/2018	10382	Order re Plaintiff's use of the depositions of Drs. Moritz, Rogers, and Stein at trial
03/19/2018	10489	Order re Simon Nitinol Filter complication evidence
04/18/2018	10819	Order re reconsideration motions relating to Recovery® Filter Evidence and cephalad Migration Deaths for Jones Bellwether case
04/27/2018	10920	Order re Plaintiff's motion for reconsideration of Court Order excluding evidence of Recovery® Filter Cephalad Migration Deaths for Jones Bellwether case
05/03/2018	10947	Order re Motions in Limine re (1) Case Specific Medical Issues (2) Relatives receipt of IVC Filters, (3) Experts Retained In Other Litigation, (4) Attorney Advertising, (5) Other Lawsuits for Jones Bellwether case
05/08/2018	11041	Order re cephalad migration deaths for Jones Bellwether case
05/15/2018	11082	Order re reconsideration of Recovery migration deaths
05/29/2018	11256	Order re cephalad migration, Recovery filter and deaths and FDA evidence for Jones Bellwether case
09/04/2018	12507	Order re SIR Guidelines and IFU for Hyde Bellwether case
09/07/2018	12533	Order re cephalad migration deaths, SNF as reasonable alternative design, personal opinions of Dr. Muehrcke, informed consent, FDA evidence, Surgeon General's Call to Action, and falling accidents for Hyde Bellwether case

<b>MOTIONS IN LIMINE ORDERS</b>		
<b>Date Filed</b>	<b>Doc. No.</b>	<b>Docket Text</b>
04/23/2019	17285	Order re medical care as an intervening cause of injury for Tinlin Bellwether case
04/26/2019	17401	Order re Ms. Tinlin's IVC Size, unrelated medical conditions, rates of filter complications, retrievable filter sales versus SNF sales, social security benefits, cephalad migration deaths, FDA warning letter, crisis communications plan, and patient at Dr. Muehrcke's hospital for Tinlin Bellwether case

<b>DEPOSITION DESIGNATION ORDERS</b>		
<b>Date Filed</b>	<b>Doc. No.</b>	<b>Docket Text</b>
03/07/2018	10348	Order re deposition designations for Booker Bellwether case
03/12/2018	10403	Order re deposition designations for Booker Bellwether case
03/14/2018	10438	Order re deposition designations for Booker Bellwether case
03/19/2018	10486	Order re deposition designations for Booker Bellwether case
03/21/2018	10497	Order re deposition designations for Booker Bellwether case
03/26/2018	10524	Order re deposition designations for Booker Bellwether case
05/01/2018	10922	Order re deposition designations for Jones Bellwether case
05/10/2018	11064	Order re deposition designations for Jones Bellwether case
05/11/2018	11073	Order re deposition designations for Jones Bellwether case
05/14/2018	11080	Order re deposition designations for Jones Bellwether case
05/31/2018	11313	Order re deposition designations for Jones Bellwether case
08/27/2018	12357	Order re deposition designations for Hyde Bellwether case
09/04/2018	12508	Order re deposition designations for Hyde Bellwether case
09/12/2018	12590	Order re deposition designations for Hyde Bellwether case
09/13/2018	12595	Order re deposition designations for Hyde Bellwether case
09/17/2018	12598	Order re deposition designations for Hyde Bellwether case

***In re Bard IVC Filters Products Liability Litigation, No. MDL 15-02641-PHX-DGC***

<b>DEPOSITION DESIGNATION ORDERS</b>		
<b>Date Filed</b>	<b>Doc. No.</b>	<b>Docket Text</b>
04/26/2019	17386	Order re deposition designations for Tinlin Bellwether case
05/03/2019	17513	Order re deposition designations for Tinlin Bellwether case
05/07/2019	17582	Order re deposition designations for Tinlin Bellwether case

<b>MISCELLANEOUS ORDERS</b>		
<b>Date Filed</b>	<b>Doc. No.</b>	<b>Docket Text</b>
11/10/2015	269	Amended Stipulated Protective Order re Confidentiality
11/22/2017	8872	Order re Bard's Motion for Summary Judgment on Preemption Grounds
11/22/2017	8874	Order re Bard's Motion for Summary Judgment for Booker Bellwether case
03/12/2018	10404	Order re Bard's Motion for Summary Judgment for Jones Bellwether case
03/30/2018	10587	Order re final trial preparation and setting Final Pretrial Conference for Jones Bellwether case.
06/01/2018	11321	Order re final trial preparation and setting Final Pretrial Conference for Mulkey Bellwether case.
06/28/2018	11659	Order re final trial preparation and setting Final Pretrial Conference for Kruse Bellwether case.
07/13/2018	11871	Order re final trial preparation and setting Final Pretrial Conference for Hyde Bellwether case.
07/26/2018	12007	Order re Bard's Motion for Summary Judgment for Hyde Bellwether case
08/02/2018	12061	Order re final trial preparation for Tinlin Bellwether case.
08/17/2018	12202	Order re Bard's Motion for Summary Judgment for Kruse Bellwether case
09/12/2018	12589	Order re Preemption of Negligence Per Se for Hyde Bellwether case

***In re Bard IVC Filters Products Liability Litigation, No. MDL 15-02641-PHX-DGC***

<b>MISCELLANEOUS ORDERS</b>		
<b>Date Filed</b>	<b>Doc. No.</b>	<b>Docket Text</b>
09/13/2018	12593	Order re reconsideration of Order denying Wisconsin Government Rules Rebuttable Presumption of Non-Defect for Hyde Bellwether case
10/05/2018	12853	Order re amended schedule for final trial preparation and setting Final Pretrial Conference for Mulkey and Tinlin Bellwether cases.
10/16/2018	12971	Order re amended schedule for final trial preparation and setting Final Pretrial Conference for Tinlin Bellwether case.
04/16/2019	17008	Order re Bard's Motion for Summary Judgment for Tinlin Bellwether case
05/31/2019	18038	Order re Plaintiffs Steering Committee's Motion to Modify CMO 6 to Increase the Common Benefit Assessments
03/04/2020	21461	Order Addressing Cases with Service of Process and Plaintiff Profile Form Issues, Cases for Which No Federal Jurisdiction Exists, and Duplicate Cases
07/08/2020	21527	Order re vacating dismissals of cases dismissed without prejudice

<b>MASTER AND SHORT-FORM PLEADINGS</b>		
<b>Date Filed</b>	<b>Doc. No.</b>	<b>Docket Text</b>
10/30/2015	249	CMO 2 re Setting Deadlines, First Phase of Discovery
12/17/2015	363	CMO 4 re Master Complaint, Responsive Pleadings, Short Form Complaint, Waiver, and Answer
3/17/2016	1108	Amended CMO 4 re Master Complaint, Responsive Pleadings, Short Form Complaint, Waiver, and Answer
4/20/2016	1485	Second Amended CMO 4 re Master Complaint, Responsive Pleadings, Short Form Complaint, Waiver, and Answer
12/17/2015	364	Master Complaint for Damages for Individual Claims
11/30/2015	302	Master Short Form Complaint for Damages for Individual Claims

MASTER AND SHORT-FORM PLEADINGS		
Date Filed	Doc. No.	Docket Text
12/17/2015	366	Defendants' Answer to Plaintiffs' Master Complaint
12/17/2015	365	CMO 5 re Plaintiff and Defendant Profile Forms
03/03/2016	927	Amended CMO 5 re Plaintiff and Defendant Profile Forms
03/18/2016	1153-1	Plaintiff Fact Sheet
03/18/2016	1153-2	Defendant Fact Sheet

***In re Bard IVC Filters Products Liability Litigation, No. MDL 15-02641-PHX-DGC***

**TRANSFER ORDER (FOURTH)**

**Exhibit 2 – Admitted Exhibit List from Bellwether Trials and Documents No Longer Subject to Protective Order**

<b>Trial Ex. No.</b>	<b>Notes</b>	<b>Description</b>
79		2/19/2004 Characterization of RNF - Migration resistance; TPR-04-02-02 REV 0 Test protocol for migration resistance Characterization of RNF - Migration resistance
354		9/19/2006 PPT re G2; Caudal Movement causes tilting which leads to perforation PPT last modified 3/16/2009 (custodian Mike Randall)
443		11/30/2008 G2 and G2X Fracture Analysis Reporting date range 7/1/2005 thru 11/30/2008
447		4/1/2009 Filter - Fracture Analysis (June 2010)
495		3/26/2015 Recovery Filter System; Recovery Filter Overview
504		Eclipse Concept POA
545		Altonaga Deposition, 10/22/2013, Exhibit 03 - 2/26-2/27/2004 E-mail exchange b/w Hudnall and David Rauch of BPV Re. "Case for Caval Centering"
546		Altonaga Deposition, 10/22/2013, Exhibit 04, Lehmann Deposition 4/2/13, Ex. 14 and Ferarra, Ex. 7, Barry Deposition, 01/31/2014, Exhibit 18 - 4/13-4/15/2004 E-mail exchange b/w Lee Lynch, Lehmann, and others Re. "Crisis Plan and Supporting Documents for Your Review"
552		Asch 202, 5/18/1999 Letter from Thomas Kinst, Product Manager of Filters at NMT Medical, to Monica Coutanche, Marketing Manager at Bard Canada, Inc.
553		Asch Deposition, 05/02/2016 - Exhibit 203 - 9/14/2002 Memo from Thomas Kinst to Recovery Filter Design History File Re. Recovery Filter Compassionate Use, Subject: "Conference call with Bard Peripheral Technologies regarding clinical assessment of Recovery Filter removal #5"
556		Asch Deposition, 05/02/2016 - Exhibit 207 - 1/26/2001 Letter from Mount Sinai Hospital to Dr. Asch Re. "Assessment of a New Temporary/Removable IVC Filter" - and - 11/8/2001 Letter from Mount Sinai Research Ethics Board Re. "MSH Reference #01-0161-U"
557		Asch Ex. 208, BPV-17-01-00056765 -766, /28/2000 E-mail from Paul Stagg to Cavagnaro, Mellen, Uelmen, Vierling, and Field Re. "Fwd [2]: compassionate IVC filters" (from Asch)
559		Asch Exh. 210, BPV-17-01-00052621, 4/17/2002- Email from George Cavagnaro to Doug Uelmen and Carol Vierling, dated April 18, 2002



***In re Bard IVC Filters Products Liability Litigation, No. MDL 15-02641-PHX-DGC***

**TRANSFER ORDER (FOURTH)**

**Exhibit 2 – Admitted Exhibit List from Bellwether Trials and Documents No Longer Subject to Protective Order**

<b>Trial Ex. No.</b>	<b>Notes</b>	<b>Description</b>
561		Asch Deposition, 05/02/2016 - Exhibit 212 - Special 510(k) Submission for the Recovery Filter System, K022236, dated 11/27/2002
563		Asch Deposition, 05/02/2016 - Exhibit 218 - Information for Use - Recovery Filter System, Dated 2004
567		Asch Deposition, 05/02/2016 - Exhibit 223 - 3/10/2003 Letter from Dr. Asch Re support for RF
571		Baird Deposition, 06/09/2016 - Exhibit 301 - PowerPoint Presentation entitled BPV Filter Franchise Review dated 5/6/2008 (colored and 43 pages)
587		Baird Deposition, 06/09/2016 - Exhibit 318 - Aug. 2010 Article by Nicholson et al. entitled "Online First: Prevalence of Fracture and Fragment Embolization of Bard Retrievable Vena Cava Filters and Clinical Implications Including Cardiac Perforation and Tamponade"
588		Baird Deposition, 06/09/2016 - Exhibit 319 - 11/12/2009 E-mail from Bret Baird to Bill Little, John Van Vleet, and Gin Schulz, with others CC'ed, Re. "Bard Filter Fractures presentation online"
589		Baird Deposition, 06/09/2016 - Exhibit 320 - ABA Project Agreement with BPV, Inc., dated 11/9/2010
590		Baird Deposition, 06/09/2016 - Exhibit 321 - 11/29-12/1/2010 E-mail exchange b/w Bret Baird and Jimmy Balwit Re. "White Paper, Proof 2"
591		Baird Deposition, 06/09/2016 - Exhibit 322 - Bard Idea POA on the Denali Filter, Project No. 8108 Rev. 0.0, revised August 2009 by Bret Baird
592		Baird Deposition, 06/09/2016 - Exhibit 325 - 4/28/2010 E-mail from Bret Baird to the Sales Team
614		Betensky 02/2017 Expert Report - Adverse event reports and monthly sales totals through May 2011
631		Betensky Expert Report - DFMEA070044, Rev. 3: G2 Express - Design Failure Mode and Effects Analysis
635		Betensky Expert Report - DFMEA070077, Rev. 1: Eclipse (Vail) Filter System - Design Failure Mode and Effects Analysis
677		SOF Filter Fracture Analysis, August 2010, Reporting range 7/1/05 - 8/31/10, G2, G2X, and Eclipse
691		Boyle, 02/02/2017, Exhibit 842 - E-mail chain first one from John Van Vleet to Steve Williamson, dated 11/5/2015, 6 pages

***In re Bard IVC Filters Products Liability Litigation, No. MDL 15-02641-PHX-DGC***

**TRANSFER ORDER (FOURTH)**

**Exhibit 2 – Admitted Exhibit List from Bellwether Trials and Documents No Longer Subject to Protective Order**

<b>Trial Ex. No.</b>	<b>Notes</b>	<b>Description</b>
696		Brauer Deposition, 05/23/2014 - Exhibit 16 - Testimony of Marcia Crosse, Director of Health Care, before the Subcommittee on Health, Committee on Energy and Commerce, House of Representatives Re. "Medical Devices –Shortcomings in FDA's Premarket Review, Postmarket Surveillance, and Inspections of Device Manufacturing Establishments", dated 6/18/2009
709		Brauer, 08/02/2017, Exhibit 1046 - Bard Simon Nitinol Filter, Postmarket Surveillance Study Amendment, August 10, 2014
730		Carr Deposition, 04/17/2013 - Exhibit 01 - Class of Plaintiffs' Notice of Taking Rule 30(b)(6) Deposition Duces Tecum in Case No. 12-80951- CIV-ROSENBAUM
735		Carr Deposition, 04/17/2013 - Exhibit 07 - Bard Idea POA - Eclipse Anchor Filter, caudal migration, Rev 0, 4/1/2010 E-mail exchange b/w Tracy Estrada and Ed Fitzpatrick
737		Carr Deposition, 04/17/2013 - Exhibit 09 - 8/22-8/25/2008 E-mail exchange b/w Bret Bard, Mike Randall, and Natalie Wong Re. "[Redacted] Conference call - complaint on fracture"
755		Carr Deposition, 10/29/2014 - Exhibit 3A - E-mail exchange b/w Hudnall and others from 3/9-10/4/2005 Re. "Special Accounts Roadshow"
764	REDACTED	Carr Deposition, 11/05/2013 - Exhibit 14 - 5/27/2004 E-mail b/w Greer, Carr, Hudnall, and Sullivan re. "Bariatric patients and filters", "Stay out of the buffet line", BPVE-01-00010858 -859
769		Carr Deposition, 12/19/2013 - Exhibit 05 - BPV Meridian Claims Matrix, dated 7/2/2010
770		Carr Deposition, 12/19/2013 - Exhibit 06 - Bard's Denali Concept Product Opportunity Appraisal, POA-8108, Rev. 1.0
800		Carr Deposition, 12/19/2014 - Exhibit 18 - NMT RNF PDT Meeting Notes re Product Development Team, 01/13/1998
802		Carr Deposition, 12/19/2014 - Exhibit 20 - NMT R&D Technical Report, RD-RPT-128, 09/01/2000, Investigation Report of a Migrated Recovery Filter in the Human Use Experience at Mt. Sinai Hospital
854	REDACTED	Carr Deposition, November 5, 2013 - Exhibit 15 - 12/12/2004 E-mail from Uelmen to Kellee Jones, attaching 12/9/2004 Remedial Action Plan (Revised) SPA-04-12-01

***In re Bard IVC Filters Products Liability Litigation, No. MDL 15-02641-PHX-DGC***

**TRANSFER ORDER (FOURTH)**

**Exhibit 2 – Admitted Exhibit List from Bellwether Trials and Documents No Longer Subject to Protective Order**

<b>Trial Ex. No.</b>	<b>Notes</b>	<b>Description</b>
876		Chanduszko Deposition, 04/23/2015 - Exhibit 17 - Pages 30-44 of Notebook No. 7013, Project: Recovery Filter Arm Fatigue Testing
905		Ferrara Exh. 19, BPVE-01-00245186 -188, Email chain re G2 Caudal Migrations 12/27/2005
922		Ciavarella Deposition, 11/12/2013 - Exhibit 22 - Chart of Sales and Adverse Events for all competitors from Q3/00 through Q2/03, according to the MAUDE database.
923		Ciavarella Deposition, 11/12/2013 - Exhibit 24 - Summary of Sales and Adverse Events for all competitors from 01/00 through Q1/04
924		Ciavarella Deposition, 11/12/2013 - Exhibit 26 - Chart of Sales and Adverse Events for all competitors from 01/00 through Q1 2006, according to the MAUDE database.
925		Ciavarella Deposition, 11/12/2013 - Exhibit 28 - PowerPoint presentation entitled "Filters Complaint History Data as of 7/31/2007" by Natalie Wong.
926	REDACTED	Ciavarella Deposition, 11/12/2013 - Exhibit 31 - 8/3/2005 Memo from C. Ganser to T. Ring/J. Weiland Re. IVC Recovery Filter Adverse Events (Migrations/Fractures)
927		Ciavarella Deposition, 11/12/2013 - Exhibit 35 - Health Hazard Evaluation Memo from Ciavarella to Uelmen Re. "Recovery Filter - Consultant's report", dated 12/17/2004
931		Ciavarella Deposition, 11/12/2013 - Exhibit 39 - Draft of Updated Health Hazard Evaluation Memo from Ciavarella to Uelmen, re: "Limb Fractures of Recovery Filter", dated 7/9/2004.
932		SWOT Analysis; 5/6/2008 PowerPoint presentation entitled "Filter Franchise Review" BPVE-01-00622862 - 900
945		Cohen Exh. 736, BPVE-01-00074004 - 006, IVC Filters - Covered Stents, Monthly Report April, 2004
965		Cohen Exh. 757, BPVEFILTER-01-00148562, E-mail dated 12/15/04, with attached FDA Filter Information, FDA called Temple to speak with Cohen
991		Cortelezzi, 11/11/2016, Exhibit 586 - 12/23/2005 E-mail from David Ciavarella Re. "G2 Caudal Migrations", forwarded to Brian Barry on 12/27. Worst case consequence of migrations - accompanied in a majority of tilt cases. Would like to now look at G2 complaints.

***In re Bard IVC Filters Products Liability Litigation, No. MDL 15-02641-PHX-DGC***

**TRANSFER ORDER (FOURTH)**

**Exhibit 2 – Admitted Exhibit List from Bellwether Trials and Documents No Longer Subject to Protective Order**

<b>Trial Ex. No.</b>	<b>Notes</b>	<b>Description</b>
992		Cortelezzi, 11/11/2016, Exhibit 588 - 7/16/2005 E-mail from Jason Greer to many Re. "Westy's situation...everyone's situation", detailing Bard's need to respond to Cordis' bringing forward the Maude database to physicians and "causing a problem"
994		D'Ayala Exh. 4, G2 Filter System for Permanent Placement, IFU, G2 Filter System, 10/2006, Rev. 5, PK5100030, BPV-17-01-00137425 - 432 (also used with Muehrcke)
1001		D'Ayala Exh. 13, Evidence-Based Evaluation of Inferior Vena Cava Filter Complications Based on Filter Type
1006		DeCant Deposition, 05/24/2016 - Exhibit 254 - 12/9/2003 Meeting Minutes Memo from Brian Hudson to Len DeCant, Mike Casanova, Robert Carr, and Alex Tessmer Re. "Special Design Review for Recovery (Project #'s 7081 and 8008)"
1009	REDACTED	DeCant Deposition, 05/24/2016 - Exhibit 258 - 4/6/2004 Memo from Peter Palermo to Doug Uelmen Re. "Remedial Action Plan - BPV Recovery Nitinol Vena Cava Filter", including the Remedial Action Plan SPA 04-03-01 on the Recovery Filter, dated 3/26/2004
1014	REDACTED	DeCant Deposition, 05/24/2016 - Exhibit 264 - 6/11/2004 Memo from Pete Palermo to Doug Uelmen Re. "Remedial Action Plan - BPV Recovery Filter - Migration"
1018	REDACTED	DeCant Deposition, 05/24/2016 - Exhibit 268 - 9/27/2004 Memo from Pete Palermo to Doug Uelmen Re. "Remedial Action Plan - BPV Recovery Filter - Migration (SPA-04-05-01)"
1022	REDACTED	DeCant Deposition, 05/24/2016 - Exhibit 274 - Failure Investigation Report on the Recovery Filter Migration, FIR-04-12-01 Rev. 00
1023		DeCant Deposition, 05/24/2016 - Exhibit 275 - Internal Presentation on the G2 Filter System for Permanent Use, detailing the design modifications, features/benefits, and comparison to the Recovery Filter
1031	REDACTED	Deford Deposition, 06/02/2016 - Exhibit 283 - BPV File on The Recovery Filter Migration, including Minutes from the 2/12/2004 Migration Meeting
1036		Deford Deposition, 06/02/2016 - Exhibit 296 - 9/26-9/27/2007 High Importance E-mail exchange b/w Dennis Salzmman, John Van Vleet, and John Reviere of BPV, with others CC'ed, Re. "Comments on Rev H". Discussion about concern for over-reporting of the SIR guidelines re- classification and removal of the retroperitoneal bleed, and replacing consultant John Lehmann

***In re Bard IVC Filters Products Liability Litigation, No. MDL 15-02641-PHX-DGC***

**TRANSFER ORDER (FOURTH)**

**Exhibit 2 – Admitted Exhibit List from Bellwether Trials and Documents No Longer Subject to Protective Order**

<b>Trial Ex. No.</b>	<b>Notes</b>	<b>Description</b>
1053		Edwards Deposition, 01/20/2014 - Exhibit 02 - 3/28/2003 Document RE. "Product Opportunity Appraisal for Recovery Filter", FM070018, Doc No. POA-7081, Version 000
1062		BPV PowerPoint presentation entitled "BPV/AngioMed New Product Development Review Meeting - April 26, 2004"
1130		Ferrara Exh. 3, Email Chain from Regina Busenbark to Robert Ferrara 1-12-2006
1133		Ferrera Deposition, 04/07/2017, Exhibit 11 - Recovery Filter Arm Fracture, Remedial Action Plan September 2, 2004
1140	REDACTED	Ferrera Deposition, 04/07/2017, Exhibit 25 - Presentation titled Filter-Fracture Analysis
1149		Fuller Deposition, 01/11/2016 - Exhibit 123 - NMT Report Entitled "Line Extension to the Simon Nitinol Filter®/Straight Line System, To Be Referred As: TRADEMARK Retrievable Filter"
1211		Ganser Deposition, 10/11/2016 - Exhibit 516 - 21 U.S.C.A. § 351, Adulterated Drugs and Devices, Effective 7/9/2012
1214	REDACTED	Ganser Deposition, 10/11/2016 - Exhibit 523 - Several memos: (1) 12/8/2004 BPV Memo from John McDermott to Tim Ring and John Weiland Re. "Monthly Global PV Report - November 2004"; (2) 12/8/2005 BPV Memo from John McDermott to Tim Ring and John Weiland Re. "Monthly Global PV Report - November 2005; (3) 2/10/2006 BPV Memo from John McDermott to Tim Ring and John Weiland Re. "Monthly Global PV Report - January 2006; and (4) 2/8/2007 BPV Memo from John McDermott to Tim Ring and John Weiland Re. "Monthly Global PV Report - January 2007"
1216		Ganser Deposition, 10/11/2016 - Exhibit 526 - Regulatory Affairs Manual Re. "Product Remedial Actions", RA-STD-002 Rev. 08, dated 10/12/2000
1219	REDACTED	Ganser Deposition, 10/11/2016 - Exhibit 529 - 6/30/2004 Updated Health Hazard Evaluation from David Ciavarella, M.D. to Doug Uelmen Re. "Migration of Recovery Filter"
1220	REDACTED	Ganser Deposition, 10/11/2016 - Exhibit 530 - 8/25/2004 E-mail from Avijit Mukherjee to Robert Carr, Janet Hudnall CC'ed, Re. "Recovery Filter objective statement", proposing one objective statement for the Recovery Filter G1A project, which Hudnall thought sounded "great"
1221	REDACTED	Ganser Deposition, 10/11/2016 - Exhibit 533 - 2/15/2006 Health Hazard Evaluation from David Ciavarella to Gin Schulz Re. "G2 Inferior Vena Cava Filter - Migration"

***In re Bard IVC Filters Products Liability Litigation, No. MDL 15-02641-PHX-DGC***

**TRANSFER ORDER (FOURTH)**

**Exhibit 2 – Admitted Exhibit List from Bellwether Trials and Documents No Longer Subject to Protective Order**

<b>Trial Ex. No.</b>	<b>Notes</b>	<b>Description</b>
1222	REDACTED	Ganser Deposition, 10/11/2016 - Exhibit 534 - PowerPoint Presentation for a meeting to analyze EVEREST and MAUDE data and provide justifications for proposed changes to G2 filter
1295		Graves Deposition, 02/27/2014 - Exhibit 10 - 3/23/2006 E-mail exchange b/w Mickey Graves and Charlie Simpson, FEA on G2, regarding Historical FEA analysis
1335		Hudnall Deposition, 11/01/2013, Exhibit 21 - Brochure - Recovery Cone Removal System
1336		Hudnall Deposition, 11/01/2013, Exhibit 22 - Recovery G2 Filter System brochure
1337		Hudnall Deposition, 11/01/2013, Exhibit 23 - G2 Brochure (permanent) - Patient Questions & Answers and Bard's website page about G2 Filter System, Indicated for removal, 6/10/2010
1339	REDACTED	Hudnall Deposition, 11/01/2013, Exhibit 29 - 7/6/2004 E-mail exchange b/w Hudnall and Bob Cortelezzi Re. "Maude Website Discussion"
1369		Hudson Deposition, 01/17/2014 - Exhibit 16 - 3/24/2004 E-mail from Alex Tessmer to Charlie Benware and Ed Fitzpatrick Re. "Starguide Filter Migration Test Results"
1370		Hudson Deposition, 01/17/2014 - Exhibit 18 - 12/11/2003 E-mail exchange b/w Brian Hudson and Janet Hudnall, others CC'ed, Re. "Special Design Review for Recovery - Meeting Minutes".
1383		Hudson Deposition, 01/17/2014, Exhibit 13 - BPV Engineering Test Report - Characterization of Recovery Filter Migration Resistance in Comparison to Competitive Product - Phase 1, ETR-04-03-02, Rev 0.
1500		Kessler Report - August 7, 2010, John Van Vleet emailed BPV President Jim Beasley, Marketing Director Bill Little, and V.P. of QA Gin Schulz
1517		EVEREST Track wise and MAUDE PowerPoint, BPV-17-01-00188507
1568		Kessler Report - September 30, 2010 memo from Brett Baird to Eclipse DRT, with the subject line "Eclipse Post-Market Design Review/Marketing Summary," stated: "The objective of the Eclipse Filter project was to enhance the G2 X filter surface finish..."
1578		ETR-06-28-29, revision 0, project #8049, Caudal Migration Test Method Development and G2 Filter Resistance Test Report, 11/27/06, BPVE-01-00789532

***In re Bard IVC Filters Products Liability Litigation, No. MDL 15-02641-PHX-DGC***

**TRANSFER ORDER (FOURTH)**

**Exhibit 2 – Admitted Exhibit List from Bellwether Trials and Documents No Longer Subject to Protective Order**

<b>Trial Ex. No.</b>	<b>Notes</b>	<b>Description</b>
1580	REDACTED	Kessler Report -July 12, 2004 email from Bard's VP of Regulatory Sciences Chris Ganser, to Tim Ring and John Weiland, attached "an executive summary of Recovery Filter adverse events (migration and fracture"
1594	REDACTED	Lehmann Deposition, 04/02/2013 - Exhibit 08 - 2/16/2005 E-mail from Charlie Simpson to Hudnall Re. "American Venous Forum - Mary Protocor presented an evaluation of filter related findings from the Maude database"
1612		Lehmann Deposition, 08/07/2014, Exhibit 08 - Updated Health Hazard Evaluation Memo from Ciavarella to Uelmen, re: "Limb Fractures of Recovery Filter", dated 7/9/2004
1613		Lehmann Deposition, 08/07/2014, Exhibit 09 - 6/10/2004 E-mail exchange b/w Ciavarella and Cindi Walcott Re. "Recovery Filter/Detachments"
1616		Little Deposition, 06/27/2016 - Exhibit 2003 - "Patient Questions & Answers" Brochure for the G2 Filter System
1617		Little Deposition, 06/27/2016 - Exhibit 2004 - Chart entitled "EVEREST/Cook Celest Clinical Comparison"
1618		Little Deposition, 06/27/2016 - Exhibit 2005 - 4/27/2010 BPV Memo from Filter Marketing to Bill Little Re. "Filter naming", detailing the name rational for the Eclipse and Denali
1621		Little Deposition, 06/27/2016 - Exhibit 2009 - "Fractures of a Nitinol IVC Filter" presentation by Dr. W. Jay Nicholson on www.CRTRonline.org, in which he reviewed a single center experience on fractures with the Bard Recovery and G2 filters
1643		McDermott Deposition, 02/05/2014 - Exhibit 02 - Bard's Product Performance Specification Report on the Recovery Filter and Femoral Delivery System, PPS No. PPS070016 Rev. 0
1680	REDACTED	McDonald Deposition, 07/29/2016 - Exhibit 21 - 7/13/2015 Warning Letter from the FDA regarding the 11/25/2014 Inspection of the C.R. Bard facility in NY and the 11/18/2014-1/5/2015 Inspection of the BPV facility in AZ
1740		Modra Deposition, 06/06/2014 - Exhibit 5 - 1/18/2010 E-mail from Bret Baird (Marketing Manager of IVC Filters) to Sales Team list serve (TPE-PV Sales-DG) Re. "Important: Eclipse Vena Cava Filter Launch Details"
1742		Modra Deposition, 06/06/2014 - Exhibit 7 - Product Opportunity Appraisal for the G2 Platinum Concept, POA-8088 Rev. 1.0, Revised on 5/5/2009
1763		Modra, 01/26/2017, Exhibit 771A - Chart entitled "Design Failure Mode and Effects Analysis" on the Simon Nitinol Filter - SNF/SL Filter Sets (DFMEA070042 Rev. 1)

***In re Bard IVC Filters Products Liability Litigation, No. MDL 15-02641-PHX-DGC***

**TRANSFER ORDER (FOURTH)**

**Exhibit 2 – Admitted Exhibit List from Bellwether Trials and Documents No Longer Subject to Protective Order**

<b>Trial Ex. No.</b>	<b>Notes</b>	<b>Description</b>
1787		Orms Deposition, 08/16/2016 - Exhibit 13 - 11/9/2010 E-mail Thread from Chris Smith Re. "Northside(S) Filter Business"
1788		Orms Deposition, 08/16/2016 - Exhibit 14 - 10/2/2010 E-mail Thread from Jeffrey Pellicio Re. "Meridian Commercialization Plan"
1817		Raji-Kubba Deposition, 07/18/2016 - Exhibit 301 - 5/14/2009 E-mail from Bill Edwards to Raji-Kubba and Mike Randall Re. "Tomorrow"
1821		Raji-Kubba Deposition, 07/18/2016 - Exhibit 305 - 11/12/2009 E-mail from Bret Baird to Bill Little, John Van Vleet, and Gin Schulz
1822		Raji-Kubba Deposition, 07/18/2016 - Exhibit 307 - 1/21/2010 Bard Memo from Jeffrey Pellicio to "Reviewers"
1823		Raji-Kubba Deposition, 07/18/2016 - Exhibit 308 - 1/4/2010 E-mail from Gin Schulz to Beasley, Raji-Kubba, Van Vleet, Doherty, and Little Re. "Potential Actions"
1825		Raji-Kubba Deposition, 07/18/2016 - Exhibit 310 - 9/1/2009 E-mail from Mike Randall Re. "0809 Filters Monthly Report.doc"
1861	Only admitted Pgs. 38 & 70	Randall, 01/18/2017, Exhibit 634 - Binder labeled "Meridian Design History File DHF, Vol. II"
1912		Romney Deposition, 09/07/2016 - Exhibit 2039 3/16/2006 E-mail from Jason Greer to Janet Hudnall
1926		Romney, 01/18/2017, Exhibit 2061 - 8/6/2014 E-mail from Schyler Smith, Field Manager for BPV in Washington-Idaho-Montana, to Kim Romney, Subject redacted, relaying that a redacted doctor had placed a Meridian in the past year and discovered at retrieval that an arm fractured, which imaging confirmed had occurred within 1 week of placement, and was now wondering if he should try to remove the filter or leave it in. Van Vleet forwarded to Treratola in a high importance e-mail on 8/7, requesting that he contact the doctor on Bard's behalf.
1940	REDACTED	Schulz Deposition, 01/30/2014 - Exhibit 11 - Chart of Adverse Events and Deaths for all competitors from Prior Evaluation through Q3 2005 and from
1941	REDACTED	Schulz Deposition, 01/30/2014 - Exhibit 12 - 11/30/2005 E-mail exchange b/w Gin Schulz and Kellee Jones re Gin, G2 v. Maude and attachments, Spread Sheet - Filter Sales (IMS Q1 '00 to Q4 '04, + Trend Q1 - Q3 '05)



***In re Bard IVC Filters Products Liability Litigation, No. MDL 15-02641-PHX-DGC***

**TRANSFER ORDER (FOURTH)**

**Exhibit 2 – Admitted Exhibit List from Bellwether Trials and Documents No Longer Subject to Protective Order**

<b>Trial Ex. No.</b>	<b>Notes</b>	<b>Description</b>
1944		Schulz Deposition, 01/30/2014 - Exhibit 15 - 5/19/2006 E-mail from Natalie Wong to Gin Schulz and Candi Long, attaching the PowerPoint Presentation on "Recovery (Gen 1) Fracture Slides" (included in exhibit) and RNF Fracture Report (not included), updated to be current as of 5/18/2006 for the Management Review
1945		Schulz Exh. 16, BPVEFILTER-01-00008798 - 851, 10/1/2006 E-mail from Natalie Wong to Several Re. "Fracture Docs"
1946		Schulz Deposition, 01/30/2014 - Exhibit 17 - 2/2/2006 E-mail from Gin Schulz to Several Re. "Minutes"
1947		Schulz Deposition, 01/30/2014 - Exhibit 19 - 5/10/2006 E-mail from Natalie Wong Re. "FDA Proposed Response"
1948		Schulz Deposition, 01/30/2014 - Exhibit 2 - 1/31/2006 E-mail from Gin Schulz to Mickey Graves and Natalie Wong Re. "Caudal"
1949		Schulz Deposition, 01/30/2014 - Exhibit 21 - 6/28/2011 Email Chain from Brian Hudson to Kevin Bovee and Chad Modra Re Talking Points Including attachment
1950		Schulz Deposition, 01/30/2014 - Exhibit 4 - Meeting Summary of the IVC Filter Focus Group meeting held on 6/1/2006 in Chicago, IL at Hilton O'Hare
1951		Schulz Deposition, 01/30/2014 - Exhibit 5 - 1/31/2005 Memo from Peter Palermo to Kerry Chunko Re. "Quality Plan 2005"
2045		Sullivan Deposition, 09/16/2016 - Exhibit 431 - Marketing Brochure - G2 Filter System for Permanent Placement
2048	REDACTED	Sullivan Deposition, 09/16/2016 - Exhibit 437 - Document entitled "Failure Investigations/R002 History Review"
2049		Sullivan Deposition, 09/16/2016 - Exhibit 439 - 11/17/2004 Updated Health Hazard Evaluation Memo from David Ciavarella, M.D. to Doug Uelmen, Re: "Limb Fractures of Recovery Filter"
2052		Wong Exh. 546, BPVE-01-01239757 - 775, Draft of PowerPoint Presentation entitled "G2 and G2X Fracture Analysis", dated 11/30/2008
2057	REDACTED	Sullivan, 11/03/2016, Exhibit 442 - Recovery Filter Migration Remedial Action Plan SPA-04-12-01 dated 1/4/2005, including the Lehmann Report and Dr. Ciavarella's 12/17/2004 HHE titled "Recovery Filter - Consultant's report"
2059		Tessmer Deposition, 06/12/2013 - Exhibit 02 - Project Status Report Form for the Recovery Filter, Project No. 7081, initiated 7/1/2002 with the goal to "Investigate Migration"; FM0700160, Rev. 1

***In re Bard IVC Filters Products Liability Litigation, No. MDL 15-02641-PHX-DGC***

**TRANSFER ORDER (FOURTH)**

**Exhibit 2 – Admitted Exhibit List from Bellwether Trials and Documents No Longer Subject to Protective Order**

<b>Trial Ex. No.</b>	<b>Notes</b>	<b>Description</b>
2061		Tessmer 5, BPVE-01-00000230, 2/4/2004 E-mail from Alex Tessmer to Several Re. "Updated: Filter Migration Flow Loop Test Fixture"
2062		Tessmer Deposition, 06/12/2013 - Exhibit 07 - 1/14/2004 Memo from Rob Carr to File Re. "Design Review Meeting Minutes Response"
2063		Tessmer Deposition, 06/12/2013 - Exhibit 08 - 2/25/2004 E-mail from Alex Tessmer to Robert Carr and Brian Hudson Re. "Filter Migration Test Results"
2065		Tessmer Deposition, 06/12/2013 - Exhibit 11 - BPV Engineering Test Report - Characterization of Recovery Filter Migration Resistance When Legs are Crossed or Hooks Removed - Phase 2, ETR-04-03-10, Rev 0
2068		Tessmer Deposition, 06/12/2013 - Exhibit 17 - 6/8/2004 "High" Importance E-mail from Alex Tessmer to Carr, Chandusko, and Hudson Re. "Filter Improvement DOE"
2069		Tessmer Deposition, 06/12/2013 - Exhibit 19 - 8/26/2004 E-mail from Alex Tessmer to Robert Carr and Avijit Mukherjee Re. "Corporate Presentations"
2090		Tillman, 08/04/2017, Exhibit 1064 - NMT PowerPoint, Cprdos, 06/14/2000
2105		Trerotola, 01/20/2017, Exhibit 692 - 4/30/2015 E-mail from Dr. Trerotola to John Van Vleet, forwarding an article from Forbes Magazine about ALN filters entitled "Effect of a Retrievable IVC Filter Plus Anticoagulation vs. Anticoagulation Alone on Risk of Recurrent PE: A Randomized Clinic Trial". Per Trerotola, "not good for ALN...and maybe not good for the industry". The article was discussed through 5/4, as they were meeting that day to review articles before meeting with JVV.
2149		Vierling Deposition, 05/11/2016 - Exhibit 231 - 12/13/2001 E-mail from Carol Vierling to kaufmajo@ohsu.edu, Paul Stagg, and Connie Murray Re. "RF Protocol"
2153		Vierling Deposition, 05/11/2016 - Exhibit 236 - 6/3/2002 Memo from Lynn Buchanan-Kopp to Project 7081 Design History File Recovery Filter Project Team Re. "Project Phase Clarification", defining the 3 phases of the Recovery filter project (I. Permanent; II. Intraprocedural Removal; and III. Long-Term Removable), as decided at the project team meeting on 5/20/2002
2217		Williamson Deposition, 09/07/2016 - Exhibit 105 - Cover page entitled "Attachment 1.14", followed by the 1/23/2015 Memo from Ludwig to Chad Modra Re. "IVC Filters Retrospective Review", detailing the 2-year review

***In re Bard IVC Filters Products Liability Litigation, No. MDL 15-02641-PHX-DGC***

**TRANSFER ORDER (FOURTH)**

**Exhibit 2 – Admitted Exhibit List from Bellwether Trials and Documents No Longer Subject to Protective Order**

<b>Trial Ex. No.</b>	<b>Notes</b>	<b>Description</b>
		of 939 filter complaints from 1/2013 to 1/2015, with a chart detailing whether the MDR classification changed for any complaints
2238		Wilson, 01/31/2017, Exhibit 801 - E-mail string, Subject: Meridian Commercialization Plan
2243		Wong Deposition, 10/18/2016 - Exhibit 537 - 4/23/2004 E-mail from John Lehmann to Carr and Uelmen Re. "Draft data set for statistician"
2244	REDACTED	Wong Deposition, 10/18/2016 - Exhibit 538 - 12/17/2004 Health Hazard Evaluation from David Ciavarella to Doug Uelmen Re. "Recovery Filter - Consultant's Report", detailing the 76 reports of the Recovery filter, with 32 serious injury and 10 deaths of the 20,827 units sold during the reporting period
2245		Wong Exh. 540, Recovery Gen 1, Fracture and Migration Complaint Update, 6-20-2006
2245		Wong Deposition, 10/18/2016 - Exhibit 540 - Confidential PowerPoint Presentation entitled "Recovery (Gen 1) - Fracture and Migration Complaint Update," dated 6/20/2006
2246		Wong Exh. 541, BPVE-01-01512188, Email from Natalie Wong to Gin Schulz Re RNF Fracture Report 8-1-06, 8-4-2006
2247		Wong Deposition, 10/18/2016 - Exhibit 542 - 12/2/2009 E-mail exchange b/w Sandy Kerns and Natalie Wong Re. "Filter Fractures"
2248		Wong Deposition, 10/18/2016 - Exhibit 543 - PAT PowerPoint Presentation entitled "G2 Caudal Migration Update," dated 3/2/2006, which Wong circulated via e-mail on 3/2/2006 to several for the presentation that afternoon
2249		Wong Deposition, 10/18/2016 - Exhibit 544 - 5/18/2006 Natalie Wong meeting documents, email re "Caudal Investigation" with attachments of G2 Caudal Report 05.18.06 and Caudal Pre-PAT minutes
2250		Wong Deposition, 10/18/2016 - Exhibit 545 - BPV's Failure Investigation Report on the G2 Filter - Caudal Migration, FIR-06-01-01, unsigned and forwarded by Wong to Gin Schulz for her review, in anticipation of the Friday deadline
2251		Wong Deposition, 10/18/2016 - Exhibit 547 - 4/10/2006 High Importance E-mail from Cindi Walcott to Allen, Schulz, and McDermott Re. "FW: FDA Request for Information"
2252		Wong Deposition, 10/18/2016 - Exhibit 548 - 9/25/2007 E-mail from John Lehmann to John Van Vleet and John Reviere Re. "EVEREST FSR rev H and supporting redlines

***In re Bard IVC Filters Products Liability Litigation, No. MDL 15-02641-PHX-DGC***

**TRANSFER ORDER (FOURTH)**

**Exhibit 2 – Admitted Exhibit List from Bellwether Trials and Documents No Longer Subject to Protective Order**

<b>Trial Ex. No.</b>	<b>Notes</b>	<b>Description</b>
2253		Wong Deposition, 10/18/2016 - Exhibit 549 - 5/27/2004 E-mail from Natalie Wong to Doug Uelmen Re. "Recovery Stats"
2254		Wong Deposition, 10/18/2016 - Exhibit 552 - 2/17/2006 Memo from Mickey Graves and Natalie Wong Re. "Recovery Filter (Generation 1) Product Assessment Team Minutes - Fractures"
3262	REDACTED	Complaint File - 03/09/2010, 263280, G2 - RF310F, 2907 Detachment of device or device component
3270	REDACTED	Complaint File - 03/30/2010, 266286, G2 - RF310F, 2907 Detachment of device or device component
3304	REDACTED	Complaint File - 07/28/2010, 282326, Eclipse - EC500J, 2907 Detachment of device or device component; 2907M Filter Limb(s)
3572		Securities and Exchange Commission Form 10-K for C.R. Bard, Inc. for the fiscal year ended December 31st, 2016
3573		Securities and Exchange Commission Form 10-Q for C.R. Bard, Inc. for the quarterly period ended September 30th, 2017
4327	REDACTED	2/10/06 monthly meeting - redesign due to caudal migration (excludes last 4 pages)
4328		Ganser Exh. 517 Device Labeling Guidance, General Program Memorandum
4330		Asch Deposition, 05/02/2016 - Exhibit 206, July 21, 1999 letter to Dr. Freeland from Dr. Asch
4332		Updated CV of Murray Asch
4392		Truthfulness and Accuracy Statement Vierling Deposition, Exhibit 227
4409		G2 Brochure 2
4412		Email from: Gin Schulz to Kevin Shiffrin regarding Recovery Filter Limb Fractures with attachment of RF Limb detach
4414		Email from Brian Reinkensmeyer to Baird cc Pellicio and Randall re "Filter study Idea"
4415		Email from Mike Randall to Carr and Raji-Kubba re "Misclassified??"
4416		Bill Little email re Eclipse Filter Naming
4420	REDACTED	Meridian Vena Cava Filter and Jugular Delivery System Product Performance Specification PPS, Revision 3

***In re Bard IVC Filters Products Liability Litigation, No. MDL 15-02641-PHX-DGC***

**TRANSFER ORDER (FOURTH)**

**Exhibit 2 – Admitted Exhibit List from Bellwether Trials and Documents No Longer Subject to Protective Order**

<b>Trial Ex. No.</b>	<b>Notes</b>	<b>Description</b>
4428		Eclipse Vena Cava Filter Ad
4430		Eclipse Vena Cava Filter Brochure
4433		Eclipse Vena Cava Filter Patient Questions & Answers
4438		G2 Express Vena Cava Filter Brochure
4454		Eclipse Vena Cava Filter Concept POA, Revision 2
4455		Vail Vena Cava Filter DIS
4456		Eclipse Vena Cava Filter Product Performance Specification (PPS)
4457		Vail Filter System DFMEA
4459		Eclipse Vena Cava Filter Jugular Vein Approach IFU
4467		8/12/2011 email from Mike Randall to Joni Creal re Corp approval needed for Cleveland Clinic Studies w/ attached PowerPoint slides re Filter Fixation and Migration: Forces and Design
4468		6/10/2011 email from Mike Randall re Meridian Presentation for SSM 2011
4469		Data Source Evaluation memo from Natalie Wong to Quality Systems Coordinator, October 2010
4486		G2 Express Project Plan FM0700150 Rev 6 1-30-07
4499		Meridian Vena Cava Filter vs. Eclipse Vena Cava Filter
4504	REDACTED	Monthly Management Report, dated 4/8/09
4507	REDACTED	Monthly Management Report, dated 7/9/09
4509	REDACTED	Monthly Management Report, dated 10/8/09
4512	REDACTED	Monthly Management Report, dated 1/1/10
4514	REDACTED	Monthly Management Report, dated 3/8/10
4515	Only admitted pgs. 12 & 13	Monthly Management Report, dated 4/8/10

***In re Bard IVC Filters Products Liability Litigation, No. MDL 15-02641-PHX-DGC***

**TRANSFER ORDER (FOURTH)**

**Exhibit 2 – Admitted Exhibit List from Bellwether Trials and Documents No Longer Subject to Protective Order**

<b>Trial Ex. No.</b>	<b>Notes</b>	<b>Description</b>
4519	REDACTED	Monthly Management Report, dated 8/9/10
4522	REDACTED	Monthly Management Report, dated 11/8/10
4528	REDACTED	Monthly Management Report, dated 5/9/11
4532	REDACTED	Monthly Management Report, dated 9/9/11
4533	REDACTED	Monthly Management Report, dated 10/10/11
4534	REDACTED	Monthly Management Report, dated 11/8/11
4552		Decant Deposition Exhibit 273, Failure Investigation Report, Recovery Filter Migration FIR-04-12-02, Rev. 00
4554		NMT Medical, BSC Presentation, 5/22/2000
4565		FRE 1006 Chart - Plaintiff's Compilation Complaint Record Detail
4595		Kandarpa Deposition, 07/19/2018 - Exhibit 05 - Medical Monitor Meeting Minutes, August 29, 2005, Beechwood Hotel, Worcester, MA, Version 1.0 (6 pages), signed 12/16/05. *only the last page is bates stamped BBA-00012962
4596		Kandarpa Deposition, 07/19/2018 - Exhibit 06 - Everest Clinical Trial, Medical Monitor Meeting agenda and power point, June 19, 2006, Revision B
4599		Kandarpa Deposition, 07/19/2018 - Exhibit 09 - Summary of Filter Movement, 5mm or greater, Final Clinical Summary Report EVEREST
4600		Kandarpa Deposition, 07/19/2018 - Exhibit 10 - Device Observation Table (as of 10/23/2006)
4601		Kandarpa Deposition, 07/19/2018 - Exhibit 11 - Listing of Device Observations, Final Clinical Summary Report EVEREST
4602		Kandarpa Deposition, 07/19/2018 - Exhibit 12 - Adjudication Manual of Operations, EVEREST (trial exhibit 5983
4603		Kandarpa Deposition, 07/19/2018 - Exhibit 13 - Recovery G2 Filter System - Femoral and Jugular/Subclavian Delivery Kits, Tradition 510(k), October 31, 2007
4604		Kandarpa Deposition, 07/19/2018 - Exhibit 14 - Article entitled "Technical Success and Safety of Retrieval of the G2 Filter in a Prospective, Multicenter Study", Nov. 2009

***In re Bard IVC Filters Products Liability Litigation, No. MDL 15-02641-PHX-DGC***

**TRANSFER ORDER (FOURTH)**

**Exhibit 2 – Admitted Exhibit List from Bellwether Trials and Documents No Longer Subject to Protective Order**

<b>Trial Ex. No.</b>	<b>Notes</b>	<b>Description</b>
4607		Kandarpa Deposition, 07/19/2018 - Exhibit 17 - Memorandum dated June 21, 2006 Subject: G2 Caudal Migration Failure Investigation Team Agenda, From Natalie Wong
4617		VanVleet Deposition, 09/26/2016 - Exhibit 496 - Bard Recovery G2 EVEREST Final Study Report
4785		Fermanich Deposition, 3/17/17 - Exhibit 2: Email, from Tim Hug, 3/19/10, Re: Adversity-How are you going to respond (6 pages)
4786		Fermanich Deposition, 3/17/17 - Exhibit 3: Email, from Tim Hug, 4/27/10, Re: Flair-April Expected Results (3 pages)
4794		Fermanich Deposition, 3/17/17 - Exhibit 11: Email from Tim Hug to Hans Yentz (and others), 2/9/10, Subject: Filter Accounts-Eclipse Transition (2 pages)
4795		Fermanich Deposition, 3/17/17 - Exhibit 12: G2 Filter product brochure (4 pages)
4797		Fermanich Deposition, 3/17/17 - Exhibit 14: Email from Tim Hug to Nine Aghakhan (and others), 3/24/10, Subject: FW: G2 X not available for order (2 pages)
4798		Fermanich Deposition, 3/17/17 - Exhibit 15: Email from Bret Baird to TPW-PV Sales-DG, 4/28/10, Subject: When was the last time... (2 pages)
4800		Fermanich Deposition, 3/17/17 - Exhibit 17: Email from David Ciavarella to Brian Berry (and others), 12/27/05, Subject: FW: G2 Caudal Migrations (2 pages)
4804	Only admitted 1st email, redacted other emails	Fermanich Deposition, 3/17/17 - Exhibit 21: Email from Mary Christine Starr to Matt Fermanich, 2/17/11, Subject: RE: Technician Registration (4 pages)
4806	Only admitted pg. 2	Fermanich Deposition, 3/17/17 - Exhibit 23: Email from Cynthia L. Haas to Matt Fermanich, 4/21/11, Subject: RE: Expired product (7 pages)
4809		Fermanich Deposition, 3/17/17 - Exhibit 26: Email from Tim Hug to Matt Fermanich, 12/13/00, Subject: G2 Filter Discontinued (2 pages)

***In re Bard IVC Filters Products Liability Litigation, No. MDL 15-02641-PHX-DGC***

**TRANSFER ORDER (FOURTH)**

**Exhibit 2 – Admitted Exhibit List from Bellwether Trials and Documents No Longer Subject to Protective Order**

<b>Trial Ex. No.</b>	<b>Notes</b>	<b>Description</b>
4812		Fermanich Deposition, 3/17/17 - Exhibit 29: BPV Memo from Filter Marketing to Bill Little, 4/27/10, Subject: Filter naming (2 pages)
4820		Fermanich Deposition, 3/17/17 - Exhibit 37: Health Hazard Evaluation memo from David Ciavarella to Gin Schulz, 2/15/06, Re: G2 Inferior Vena Cava Filter - Migration (3 pages)
4842		Hug Deposition, 8/23/17 - Exhibit 1117: Email to Nine Aghakhan from Tim Hug, 3/8/11, Subject: FW: GW Fem Filter Backorder (2 pages)
4893		GX2 Risk Analysis
4894		Eclipse Risk Analysis
4895		Meridian Risk Analysis
4896		Caudal Migration Testing Meridian and Optease
4897		G2 Express Product Performance Specification, PPS-8058
4938		BPV Consulting Request Form
5001		Dec. 2004 Dear Doctor Letter
5003		Feb. 8, 2005 Conference FDA and BPV re Recovery Retrievable (K031328)
5017		Aug. 5, 1999 R&D Technical Report RNF Migration Study, Design Verification (RD-RPT-100)
5022		RD-LNB-087 Laboratory Notebook
5037		ETR-05-02-02 (Effects of Changes to the Recovery Filter & The Femoral Delivery System on Filter Stresses Based on FEA Analysis)
5126		Guidance for Industry and FDA Reviewers/Staff - Guidance for Cardiovascular Intravascular Filter 510(k) Submissions
5126		Guidance for Industry and FDA Reviewers/Staff - Guidance for Cardiovascular Intravascular Filter 510(k) Submissions
5164		July 8, 2003 Fax IMPRA to FDA re Recovery Retrievable (K031328)



***In re Bard IVC Filters Products Liability Litigation, No. MDL 15-02641-PHX-DGC***

**TRANSFER ORDER (FOURTH)**

**Exhibit 2 – Admitted Exhibit List from Bellwether Trials and Documents No Longer Subject to Protective Order**

<b>Trial Ex. No.</b>	<b>Notes</b>	<b>Description</b>
5169	REDACTED	Apr. 25, 2003 Recovery Retrievable Abbreviated 510(k) (K031328)
5177		Nov. 27, 2002 FDA Clearance Letter re Recovery Permanent (K022236) (Substantial Equivalence)
5178		Oct. 25, 2002 Letter IMPRA to FDA re Recovery (K022236)
5179		Oct. 4, 2002 Letter FDA to IMPRA re Recovery (K022236)
5182		Aug. 30, 2002 Letter IMPRA to FDA re Recovery (K022236)
5187		Aug. 5, 2002 Letter FDA to IMPRA re Recovery (K022236)
5189		July 10, 2002 IMPRA Recovery Permanent Special 510(k) (K022236)
5193		Feb. 28, 2005 Letter BPV to FDA re FDA AI re Recovery Retrievable (K031328)
5195		Nov. 30, 2004 Letter FDA to BPV re Recovery IFU and DDL, dear doctor letter
5196		Oct. 5, 2004 Letter BPV to FDA re Recovery IFU and DDL
5197		July 25, 2003 FDA Clearance Letter re Recovery Retrievable (K031328) (Substantial Equivalence)
5232		RD-RPT-116 (RNF Migration Study) (Test report for RD-SOP-035.02) RD-RPT-116
5233		RD-SOP-054.00 (Recovery Filter Endura TEC Fatigue Testing SOP NMT)
5234		RD-RPT-099 (Recovery Filter Endura TEC Fatigue Testing Report NMT)
5238		Slides from Bariatric Surgeons Panel Meeting on Feb. 12, 2005
5239		Jan. 21, 2005 Conference FDA and BPV re DDL and Recovery Retrievable (K031328)
5247		May 11, 2005 BPV began distributing DCL
5252		ETR-04-03-02 (RNF v. Competitive Product -- migration resistance)
5268		NMT's 510(k) (K963016) for modifications to the SNF(submitted by Hogan & Hartson)
5272		Nov. 23, 2009 BPV's Eclipse Filter System Special 510(k) (K093659)
5273		Jan. 14, 2010 FDA Clearance Letter Eclipse Filter (K093659) (Substantial Equivalence)

***In re Bard IVC Filters Products Liability Litigation, No. MDL 15-02641-PHX-DGC***

**TRANSFER ORDER (FOURTH)**

**Exhibit 2 – Admitted Exhibit List from Bellwether Trials and Documents No Longer Subject to Protective Order**

<b>Trial Ex. No.</b>	<b>Notes</b>	<b>Description</b>
5283		G2 IFU (Femoral) PK5250500 Rev. 0 01/08
5290		TD-00456 (EVEREST Study Final Report)
5296		G2 Filter Product Performance Specification, v.2
5301		ETR-05-01-06 Animal Model Evaluation of Recovery Filter G1A Femoral System Report
5302		TPR 05-01-13 G1A Recovery Filter Femoral System Design Verification and Validation Protocol
5303		ETR-05-02-05 (G2® DV&V summary testing)
5304		ETR 05-02-11 G1A Recovery Filter Femoral System Chronic Animal Study Report
5315		Phase 2 Design Review G1A Recovery Filter Femoral Delivery System, BPV-17-01-00121226 -255
5316		Phase 3 Design Review (Design Review 3 & 4) G1A Recovery Filter Femoral Delivery System, BPV-17-01-00121256 -286
5322		Nov. 2, 2005 FDA Grants Full Approval of G2 Everest Study (G051304)
5323		Aug. 8, 2005 FDA Grants BPV Conditional Approval for G2 Everest Study (G050134)
5324		July 8, 2005 BPV's original IDE submission re G2 Everest Study (G050134)
5325	REDACTED	Oct. 3, 2005 Letter BPV to FDA re G2 Everest Study (G051034) and Conditional Approval
5329	REDACTED	June 21, 2006 Letter BPV to FDA re G2 Everest Study (G051304) IDE Supplement
5333		Feb. 2, 2007 Letter BPV to FDA re G2 Everest Study (G051304) Annual Progress Report
5334		Sept. 21, 2007 Letter FDA to BPV Questions re G2 Everest Study (G051304)
5335		Aug. 23, 2007 Letter BPV to FDA re G2 Everest Study (G051304) Annual Progress Report
5336		Oct. 25, 2007 Letter BPV to FDA re Responses to FDA re G2 Everest Study (G051304), BPV-17-01-00123498 -562
5339		Jan. 15, 2008 FDA Clearance Letter G2 Filter Retrievable (K073090) (Substantial Equivalence)
5340		Oct. 31, 2007 BPV's G2 Filter Retrievable Traditional 510(k) (K073090)
5343		Aug. 29, 2005 FDA Clearance Letter re G2 Permanent (K050558) (Substantial Equivalence)

***In re Bard IVC Filters Products Liability Litigation, No. MDL 15-02641-PHX-DGC***

**TRANSFER ORDER (FOURTH)**

**Exhibit 2 – Admitted Exhibit List from Bellwether Trials and Documents No Longer Subject to Protective Order**

<b>Trial Ex. No.</b>	<b>Notes</b>	<b>Description</b>
5344		July 28, 2005 Letter FDA to BPV re AI re Modified Recovery (K050558)
5348		Mar. 30, 2005 Letter FDA to BPV re Modified Recovery (K050558)
5349		Mar. 2, 2005 BPV's Modified Recovery Filter Special 510(k) (K050558)
5350	REDACTED	June 3, 2005 Letter BPV to FDA re Modified Recovery conversion Traditional 510(k) (K050558)
5352		Aug. 10, 2005 Letter BPV to FDA Responses to AI re G2 (K050558)
5353		Nov. 25, 2005 FDA Clearance Letter G2 Filter - Jugular (K052578) (Substantial Equivalence)
5354		Sept. 19, 2005 BPV's G2 Filter - Jugular Subclavian Delivery Kit Special 510(k) (K052578)
5361		Sept. 25, 2006 BPV's G2 Filter - Femoral Delivery Kit Special 510(k) (K062887)
5362		Oct. 26, 2006 FDA Clearance Letter G2 Filter - Femoral Delivery Kit (K062887)
5368		July 30, 2008 FDA Clearance Letter G2 Express Filter (K080668) (Substantial Equivalence)
5373		Mar. 7, 2008 BPV's G2 Express Filter Special 510(k) (K080668)
5376		Oct. 31, 2008 FDA Clearance Letter G2X Filter (K082305) Substantial Equivalence
5379		Aug. 12, 2008 BPV's G2X Filter Special 510(k) (K082305)
5384		G2 Express Feasibility Acute Animal Study Report TR-07-05-18
5385		G2 Express Filter Arm Fatigue Comparison TR-07-07-04
5483		sopq1417500 Rev 1 -- Statistical Complaint Trending Procedure PMA Related, BPV-17-01-00144123 - 126
5486		Dec. 17, 2009 Letter from BPV to FDA re Eclipse Filter System Response to FDA Questions (K093659)
5488		June 21, 2010 Letter from BPV to FDA re Eclipse Filter System Response to FDA Questions (K101431)
5523		ETR-04-03-05 (RNF Characterization testing comparing GFO v. NMT manufactured filters) (followed TPR-04-02-02) ETR-04-03-05, Rev. 0 (GFO and NMT Manufactured Recovery; Filters Migration Resistance Comparison, Phase 1)

***In re Bard IVC Filters Products Liability Litigation, No. MDL 15-02641-PHX-DGC***

**TRANSFER ORDER (FOURTH)**

**Exhibit 2 – Admitted Exhibit List from Bellwether Trials and Documents No Longer Subject to Protective Order**

<b>Trial Ex. No.</b>	<b>Notes</b>	<b>Description</b>
5526		TPR-04-02-02 (Protocol for RNF Migration Testing v. Competitive) Test Protocol Number TPR-04-02-02 (Rev. 0) -- Characterization of the Recovery Filter (RF) - Migration Resistance
5534		Picture of Clot from Feb. 2004 RNF Migration
5536		Meeting Summary from Filter Expert Panel June 1, 2006
5537		June 2006 Expert Panel Meeting Slides
5539	Only admitted pgs. 12 -32	G2 Caudal Migration Failure Investigation Report Aug. 4, 2005 G2 Filter Caudal Migration Failure Investigation Report (FIR-06-01-01) G2 Caudal Migration Failure Investigation Report
5560		Standard Operating Procedures / Division Operating Procedures -- CQA-STD-R002 Rev 11, BPV-17-01-00166749 - 776.
5561		Standard Operating Procedures / Division Operating Procedures -- CQA-STD-R002 Rev 12, BPV-17-01-00166777 - 806
5563		Standard Operating Procedures / Division Operating Procedures -- CQA-STD-R002 REv 14
5565		Standard Operating Procedures / Division Operating Procedures -- RA-STD-002 Rev 10
5586		May 20, 2010 BPV's Eclipse Filter Special 510(k) (K101431)
5587		June 18, 2010 Letter FDA to BPV re FDA AI Demand re Eclipse (K101431)
5588		Dec. 15, 2009 Letter FDA to BPV re FDA AI Demand re Eclipse (K093659)
5589		June 22, 2010 - FDA Clearance Letter for Eclipse Filter (K101431) (Substantial Equivalence)
5593		Aug. 14, 2009 Conference FDA and BPV re future Eclipse Filter 510(k)
5602	REDACTED	FDA CONTACT REPORT January 7 2010 FINAL
5612	REDACTED	Nov. 17, 2009 (Filters and future submissions)
5691	Only admitted pgs. 12-32	BPV FDA 483 Update Response March 26, 2015, BPV-17-01-00200156 - 338

***In re Bard IVC Filters Products Liability Litigation, No. MDL 15-02641-PHX-DGC***

**TRANSFER ORDER (FOURTH)**

**Exhibit 2 – Admitted Exhibit List from Bellwether Trials and Documents No Longer Subject to Protective Order**

<b>Trial Ex. No.</b>	<b>Notes</b>	<b>Description</b>
5706	Only admitted pgs. 48-61	September 3 2015 Update Response to Warning Letter issued July 13 2015.pdf
5851		TD-04698 Retrospective IVC Filter Review.pdf
5872		FDA Warning Close Out Letter
5874		Bard filter rate information December 2016
5877		1996 Memo from Veronica Price
5879		April 11, 2006 Letter to FDA re Caudal Migration
5880		March 23, 2006 Letter to FDA re G2 Caudal Migration
5881		May 11, 2006 Letter to FDA re Caudal Migration
5905		Jan. 22, 2005 Email to FDA
5923	REDACTED	September 2010 Letter to Clinicians re FDA PHN
5929		TR-07-12-01 (Test Report re G2 Express DV& V Flat Plate Fatigue and Corrosion)
5931		G2X (Jugular) 2009.10 – PK5100070 rev. 5 IFU
5942		January 7, 2010 FDA PowerPoint Presentation
5946		QMBR—July 2006
5949		ETR-06-05-02 (Test report re G2® Clot Trapping Efficiency)
5967		G2 Risk Benefit Analysis (RBA-0003, Rev. 0)
5970		HHE re G2 Caudal Migration February 15, 2006
5991		FM1287100 Rev. 5 (MDR Reportability Guidelines)
5994		TD-04316 Nov. 4, 2015 FDA and Bard Teleconference
5995		TD-04326 Oct. 26, 2015 FDA and Bard Teleconference
6013		Dec. 27, 2010 Letter from BPV to FDA re Meridian

***In re Bard IVC Filters Products Liability Litigation, No. MDL 15-02641-PHX-DGC***

**TRANSFER ORDER (FOURTH)**

**Exhibit 2 – Admitted Exhibit List from Bellwether Trials and Documents No Longer Subject to Protective Order**

<b>Trial Ex. No.</b>	<b>Notes</b>	<b>Description</b>
6046		August 28, 2006 EVEREST Medical Monitor Adjudication Meeting Minutes
6061		Aug. 22, 2005 Internal FDA memo reviewing BPV's Responses to FDA AI re G2 (K050558)
6064		July 26, 2005 Internal FDA memo re BPV Responses to FDA AI re Modified Recovery (K050558)
6075		Nov. 10, 2004 FDA Internal Memo re Dear Doctor Letter
6082		FDA_PRODUCTION_00001288 -- July 2, 2003 Email chain FDA and BPV re Recovery Retrievable (K031328)
6089		Product Development Cycle PPT
6842	***	ACR-SIR-SPR Practice Parameter for the Performance of Inferior Vena Cava (IVC) Filter Placement for the Prevention of Pulmonary Embolism. Revised 2016.  <b>Note:</b> “Admitted for the limited purpose to establish knowledge to the medical community, not for the truth of the matter asserted.”
6892		Binkert CA, Drooz AT, Caridi JG, Sands MJ, Bjarnason H, Lynch FC, Rilling WS, Zambuto DA, Stavropoulos SW, Venbrux AC, Kaufman JA. Technical success and safety of retrieval of the G2 filter in a prospective, multicenter study. J Vasc Interv Radiol. 2009 Nov;20(11):1449-53. doi: 10.1016/j.jvir.2009.08.007.
6991		FDA Safety - Inferior Vena Cava (IVC) Filters: Initial Communication: Risk of Adverse Events with Long Term Use, 08/09/2010.
6992		FDA Safety Communications, Removing Retrievable Inferior Vena Cava Filters. 05/06/2014. <a href="http://wayback.archive-it.org/7993/20170722215731/https://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm396377.htm">http://wayback.archive-it.org/7993/20170722215731/https://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm396377.htm</a>
6993		FDA Safety Communications, Removing Retrievable Inferior Vena Cava Filters: Initial Communication. 08/09/2010. <a href="http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm221676.htm">http://www.fda.gov/MedicalDevices/Safety/AlertsandNotices/ucm221676.htm</a>
7312	***	SIR Guidelines for IVC Filters  <b>Note:</b> “Admitted for the limited purpose to establish knowledge to the medical community, not for the truth of the matter asserted.”

***In re Bard IVC Filters Products Liability Litigation, No. MDL 15-02641-PHX-DGC***

**TRANSFER ORDER (FOURTH)**

**Exhibit 2 – Admitted Exhibit List from Bellwether Trials and Documents No Longer Subject to Protective Order**

<b>Trial Ex. No.</b>	<b>Notes</b>	<b>Description</b>
7411		2008 Surgeon General's Call to Action re PE and DVT
7753		2014 Draft FDA Guidance re Benefit-Risk Factors When Determining Substantial Equivalence in Premarket Notifications 510k with Different Technological Characteristics
7758		2014 FDA Guidance re 510k Evaluating Substantial Equivalence in Premarket Notifications
7771		Braun Vena Tech LP Femoral – October 2010
7787		Cordis Optease Femoral Jugular Antecubital - 2013
7795		Screenshot from FDA, MAUDE - Manufacturer and User Facility Device Experience, available online at <a href="https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/search.cfm">https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/search.cfm</a>
7960		IVC Filters Clinical Overview
7961		Corporate Quality Assurance Manual, Standard for Product Complaint Handling
7962		Corporate Quality Assurance Manual, Standard for Medical Device Reporting
7900		Demonstrative depiction of sales of bard's retrievable IVC filters
8325		Eclipse IFU 02.2010 PK5100600 Rev. 1
8358		TR-09-10-15 -- Eclipse Flat Plate Fatigue and Corrosion Examination of the Vail (Eclipse) Filter
8359		TR-09-10-16 DV&V Eclipse Filter Arm Fatigue Comparison Study (Project #8113)
8362		Eclipse Filter Patient Questions & Answers
8368		TP-09-10-15 Rev. 0 - Eclipse DV&V Flat Plate Fatigue and Corrosion Test Protocol
8482		Bard IVC Filter G3 Design/Development Timeline
8546		Draft Test Report re Rotary Beam Fatigue of Nitinol Wire
8572		G3 Meeting Minutes Nov 27, 2007
8574		TR 09-10-10, Test Report Cyclic Fatigue Testing of Electropolished Vail Filter Wire
8575		TP 09-10-10, Test Protocol Cyclic Fatigue Testing of Electropolished Vail Filter Wire

*In re Bard IVC Filters Products Liability Litigation*, No. MDL 15-02641-PHX-DGC

**TRANSFER ORDER (FOURTH)**

**Exhibit 2 – Admitted Exhibit List from Bellwether Trials and Documents No Longer Subject to Protective Order**

<b>Trial Ex. No.</b>	<b>Notes</b>	<b>Description</b>
8583		G3 Project Status Report April 19, 2006
8837		Defendants' Exhibit 10 to Joint Report on Determining Filter Type
9080		10/7/07 Email from Dr. Lehman

Document deemed no longer subject to the Protective Order

<b>Trial Ex. No.</b>	<b>Notes</b>	<b>Description</b>
908		Ciavarella Deposition, 03/01/2011 - Exhibit 12 - 5/11/2005 "Dear Colleague" letter from BPV re. the Recovery filter system